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1. INTRODUCTION 
1.1. Glioblastomas 
Glioblastomas (GBM) are devastating, treatment-refractory brain tumors [Westphal et al., 
2011]. GBM can arise de novo, in patients with no prior clinical history for brain tumors or 
after malignant progression from more benign tumors. They are the most common malignant 
brain tumors comprising 16% of all primary central nervous system malignancies [Thakkar et 
al., 2012]. Although GBMs almost always occur in the brain, they can also appear in the brain 
stem, cerebellum, and spinal cord. 61 % of all GBMs are observed in the four lobes of brain: 
25% frontal lobe, 20% temporal lobe, 13% parietal and 3% occipital lob [American Association 
of Neuroscience Nurses (AANN), 2014]. 
Initially all GBMs were thought to arise from glial cells, however, recent evidences indicate 
that a variety of cell types which have neural-progenitor-like properties might give rise to 
GBMs as well. Those cells could be at multiple stages of differentiation from neural stem cells 
to glial cells with different alterations in different signaling pathways [Parsons et al., 2008]. 
The genomic profiling that has been carried out from more than 200 human brain tumors has 
suggested more than 600 genes that have been altered. Those alterations converge onto three 
main signaling pathways that are commonly activated: p53 signaling pathway; receptor 
tyrosine kinase (RTK) / Ras / phosphoinositide-3 kinase (PI3K) signaling pathways; and 
retinoblastoma pathway [Chen et al., 2012]. The alterations in these pathways lead to 
constant activation of cell proliferation signals, and resistance to cell death signals (enhanced 
survival) while also enabling cells to escape from cell cycle checkpoints, senescence and 
apoptosis [Alifieris et al., 2015]. Additionally, molecular fingerprints have been identified 
between primary and secondary GBMs. Typical genetic alteration for primary GBMs are 
comprised of, but not limited to, epidermal growth factor receptor (EGFR) overexpression, 
phosphate and tensin homologue (PTEN) mutations, and loss of chromosome 10q. Secondary 
GBMs mostly harbor isocitrate dehydrogenase 1 (IDH1) mutations, p53 mutations, and 
chromosome 19q loss [Reya et al., 2001; Wilson et al., 2014; Young et al., 2015]. 
Based on the alterations in the signaling pathways, three subtypes of GBMs have been termed: 
Proneural, Classical and Mesenchymal. All three subtypes harbor EGFR amplification and 
CDKN2a deletion. Moreover, classical subtype carries p53 and EGFR mutations. In addition, 
EGFRvIII, an overactive EGFR variant, is frequently observed in classical subtype. In the 
proneural subtype, PDGFRA amplification dominates along with p53 and IDH1 mutations. IDHs 
function in krebs cycle of oxidative energy production pathway in cells. Mutations in IDH genes 
lower the activity of these enzymes causing higher exposure to free radicals leading to higher 
mutation rate in DNA of those cells, a common phenomenon in cancer cells [Pollard and 
Ratcliffe, 2009]. Mesenchymal subtype harbors p53 and NF1 mutations. In accordance with 
the subtype definitions, mesenchymal subtype has been shown to be the most aggressive of 
the three subtypes with a large infiltration potential and chemoresistance, followed by 
proneural and classical [Brennan et al., 2013]. 
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Glioblastoma, being a solid tumor, harbors many different niches and different cells types 
within those niches, which altogether are termed the tumor microenvironment. The tumor 
microenvironment consists of brain tumor stem cells (BTSC) [Bao et al., 2006], endothelial cells 
and hypoxic regions [Fidoamore et al., 2016]; immune cells and immune modulatory cues 
[Ghosh et al., 2010]; astrocytes [Graeber et al., 2002]; neural stem/precursor cells (NPC) 
[Watters et al., 2005]; Mesenchymal Stem Cells (MSC) [Le et al., 2003; Aboody et al., 2000]. 
Each element within the tumor microenvironment provide the tumor cells with an intricate 
support enabling them to propagate and invade the surrounding tissue (Figure 1). 
 
 
 
1.2. Glioma Microenvironment 
1.2.1. Brain Tumor Stem Cells 
Cancer stem cells were isolated initially from people with acute myeloid leukemia (AML) 
where they were able to reproduce many features of AML in immunodeficient mice [Lapidot 
et al, 1994]. Similar discovery was made in brain tumors by Ignatova et al, where they isolated 
clonogenic neurosphere-forming cells from human glioblastoma and medulloblastoma 
postsurgery specimens and demonstrated the presence of cells with stem-like properties in 
brain tumors which later was termed Brain Tumor Stem Cells or Glioma Stem Cells (BTSCs or 
GSCs) [Ignatova et al, 2002]. This finding was further supported by Singh et al, where they 
proved the existence of a CD133+ cell population capable of forming tumors in vivo and 
neurosphere formation in vitro [Singh et al, 2004]. 
Figure 1: Many different cell types are present in the brain tumor microenvironment. Each 
cell type contributes to the tumor pathology in a unique way. Those cells include but not 
limited to brain tumor stem cells, endothelial cells, immune cells such as machrophages 
and microglia, astrocytes, neural stem / precursor cells and mesenchymal stem cells 
[Charles et al., 2011]. 
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GSCs are capable of self-renewal, multiple drug resistance and radiation resistance and high 
tumorigenicity along with expression of many stem cells markers. Such as c-Myc, SOX2, OCT4, 
NANOG, SALL4, STAT3, Bmi1, and KLF4 [Wang et al, 2008]. It has also been demonstrated that 
only four transcription factors such as POU3F2, SOX2, SALL2, and OLIG2 are enough to induce 
complete transformation of differentiated GBMs into GSCs [Suvà et al, 2014]. In addition to 
stem cell markers, the implicated signaling pathways in GSCs, which are activated frequently 
via dysregulations or mutations, mediating the self-renewal and the multipotency are Notch, 
sonic hedgehog (SHH) and Wnt/b-catenin pathways and those pathways are shared with the 
NSCs [Yi et al, 2016]. Moreover, Quakings (QKI) and Eph-Ephrin receptor ligand systems have 
emerged as part of the key signaling pathways in GSCs with potential to promote brain tumors 
due to dysfunctions. 
The QKIs belong to the heteronuclear ribonucleoprotein particle K (hnRNPK) homology (KH) 
domain family of RNA binding proteins [Bockbrader and Feng, 2008]. The QKI locus encodes 
for three major alternatively spliced genes that share RNA-binding KH domain and differ in 
their C-terminal 30 aminoacids, namely QKI-5, QKI-6 and QKI-7 [Ebersole et al., 1996]. QKI-5 
carries a nuclear localization signal targeting this isoform predominantly to nucleus whereas 
QKI-6 and QKI-7 are localized in the cytosol [Pilotte et al., 2001; Wu et al., 2002]. QKIs 
selectively interact with what are called quaking response elements (QRE) localized to intronic 
regions and mRNAs, playing roles in a variety of steps of RNA processing machinery controlling 
stability, translation and localization. They are pivotal during developmental decision 
processes and impact the glial, oligodendrocyte, and Schwann cell differentiation and 
myelination of the nervous system [Hafner et al., 2010; Galerneau and Richard, 2005; Chenard 
and Richard, 2008; Bockbrader and Feng, 2008]. 
QKIs have been shown to suppress tumorigenicity in various cancers such as colorectal cancer 
[Ji et al., 2013], clear cell renal cell carcinoma [Zhang et al., 2016] and lung cancer [Zhou et al., 
2017] via suppression of several signaling pathways involved in proliferation and invasion. In 
brain tumors, a dichotomous role has been attributed to QKIs. They have been shown to 
inhibit GBM tumorigenesis by Li et al., Chen et al., and Shingu et al. [Li et al., 2002; Chen et al., 
2012; Shingu et al., 2017]. On the other hand, Bandopadhayay et al. and Wang et al. 
demonstrated QKIs to promote gliomagenesis by enhancing proliferation [Wang et al., 2013; 
Bandopadhayay et al., 2016]. Therefore, it is still a controversial issue to define QKIs as pro- 
or anti-tumorigenic genes in GBM biology. 
Eph receptors constitute the largest group of receptor tyrosine kinases (RTK). They are 
transmembrane proteins which transduce signals from cell exterior to cytosol via the 
activation of their kinase domain within the cytosol upon binding of their ligands, Ephrins, to 
the extracellular domains. Ephrins are also membrane bound ligands, therefore, Eph-Ephrin 
signaling mediates cell-cell contact-dependent communication. They confer a bidirectional 
signaling affecting both the stimulant and the stimulated cell [Lisabeth et al., 2013]. 
Eph receptors and Ephrins are expressed literally in all the tissue types and are involved in a 
variety of processes, especially in developmental mechanisms governing cardiovascular and 
skeletal development, axon guidance and tissue patterning [Palmer and Klein 2003]. 
Eph/Ephrin signaling converges mostly on cell adhesion, cell sorting during embryogenesis, 
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growth cone retraction in axon guidance and cell migration [Arvanitis and Davy, 2018]. 
Recently they have also been implicated in learning and memory [Gerlai, 2002], insulin 
secretion [Konstantinova et al., 2007] and bone homeostasis [Zhao et al., 2006]. Alterations in 
Eph/Ephrin system often leads to cancer [Pasquale 2005]. 
Eph receptors contain typical RTK structure with an extracellular ligand binding domain, a 
single transmembrane domain and a cytoplasmic region with the kinase domain (Figure 2). 
There are nine EphA receptors in human genome interacting redundantly with five EphrinA 
ligands; and five EphB receptors partnering with three EphrinB ligands [Pasquale 2004; 
Paquale 2005]. Additionally, some Eph receptors have alternatively spliced forms with distinct 
roles [Zisch and Pasquale 1997]. Both EphrinAs and EphrinBs are composed of a conserved 
Eph receptor binding domain. EphrinAs are linked to the plasma membrane by a 
glycosylphosphatidylinositol (GPI) anchor, and they have been shown to be released from the 
plasma membrane to activate their EphA receptor partners at distant sites [Bartley et al. 1994; 
Wykosky et al. 2008]. Different from EphrinAs, EphrinBs contain a transmembrane region 
followed by a short cytosolic part [Holen et al., 2011]. 
Upon binding of Ephrins, Eph receptors oligomerize by interactions at various domains and 
start a signaling cascade within the cytosol, which is called the forward signaling [Barton et al., 
2013; Himanen et al., 2010]. This clustering involves interactions with actin cytoskeleton and 
may include Eph receptors of both A and B types [Janes et al., 2011]. Oligomerization leads to 
trans-phosphorylation of two conserved tyrosine residues in the juxtamembrane domain 
relieving the inhibitory intramolecular interactions via a conformational change and activating 
the kinase activity (Figure 3) [Binns et al., 2000; Zisch et al., 2000]. Eph receptors modulate 
many of the same effectors which function downstream of the other RTK families, however, 
Eph receptor signaling differs from RTK signaling due to their oligomerization mechanism 
[Wagner et al., 2013]. Activation of Eph receptors leads to recruitment of downstream 
signaling proteins that contain SH2 domains such as nonreceptor tyrosine kinases of the Abl 
and Src family as well as adaptors like Nck and Crk [Pasquale, 2010]. Moreover, PDZ domain 
carrying Rho and Ras GTPases and Akt/mTORC1 effectors bind to carboxy terminals of Eph 
receptors. Most RTKs utilize those signaling molecules to induce cell proliferation, survival and 
forward movement whereas Eph receptors cause inhibition of cell growth and activate cell 
repulsion [Lisabeth et al., 2013]. 
In addition to forward signaling commenced by the Eph receptors, Ephrin ligands also lead to 
a signaling cascade in the cells they are bound to, which is termed reverse signaling [Pasquale, 
2010]. In reverse signaling, Ephrin-B ligands are phosphorylated by Src kinases creating 
binding sites for adaptors such as Grb4. Ephrin-B signaling via Gbr4 modulates axone-pruning, 
synapse formation and dentritic spine morphogenesis in developing hippocampus [Cowan and 
Henkmeyer, 2001; Xu and Henkmeyer, 2009]. Binding of PDZ-domain-containing adaptors 
such as PDZ-RGS3 to carboxy terminal tail of Ephrin-B enables it to utilize G-protein coupled 
receptors that control neural cell migration and neural progenitor cell self-renewal [Lu et al., 
2001; Qiu et al., 2010]. The Ephrin-As do not possess a cytoplasmic domain which can interact 
with intracellular signaling proteins which renders the signaling via Ephrin-As puzzling. 
However, studies in neurons have demonstrated that they interact with neurotropin receptor 
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p75 and Ret-RTKs and the TrkBs as transmembrane interaction partners thereby leading to 
axonal guidance and branching [Lim et al., 2008; Bonanomi et al., 2012]. Consequently, via 
those interactions and other possible mechanisms, Ephrin-As are involved in many 
physiological processes such as inhibition of neural progenitor cell proliferation by Ephrin-A2 
[Holmberg et al., 2005]; modulation of glutamate uptake in glial cells in hippocampus thereby 
controlling synaptic plasticity by Ephrin-A3 [Filosa et al., 2009]; inhibition of apoptotic cell 
death in Jurkat immune cells via activation of Src family kinases and Akt by Ephrin-A4 [Holen 
et al., 2008] and control of insuling signaling in pancreatic β cells by Ephrin-A5 [Konstantinova 
et al., 2007]. Ephrin-A5 also increases cell-substrate adhesion in fibroblasts via activation of 
Src family kinase Fyn and integrins thereby controlling invasiveness which might be important 
in cancer cells as well [Campbell et al., 2006]. 
Identification of Eph/Ephrin system and cancer dates back to when the first Eph family 
member, EphA1, was isolated from a carcinoma cell line [Hirai et al., 1987]. EphrinA1 ligand 
was identified in the same way a few years later [Bartley et al., 1994]. The link between 
Eph/Ephrin system and cancer has largely accumulated over the past years. Multiple Eph 
receptors and Ephrin ligands are expressed within the tumor and tumor microenvironment. 
They have large impacts on tumor behavior via promotion of aberrant cell-cell as well as 
tumor-microenvironment communication [Surawska et al., 2004; Ireton et al., 2005]. Various 
Eph/Ephrin types have been reported in many cancer types such as prostate cancer [Huusko 
et al., 2004], colorectal cancer [Zagopoulos et al., 2008], cervical cancer [Narayan et al., 2003] 
and lung cancer [Frohling and Dohner, 2008]. Eph/Ephrin system is frequently compromised 
in brain tumors. Moreover, expression of some Eph/Ephrin pairs have been shown to be 
altered in some gliomas and due to those alterations they were suggested as possible markers 
for gliomas [Wykosky et al., 2005; Wang et al., 2008]. EphA2 is overexpressed in GBMs 
although it is not detected in normal brain regions and it has been correlated with poor 
prognosis as it promotes tumor cell proliferation and tumor angiogenesis [Wykosky et al., 
2005; Liu et al., 2006]. Additionally, EphB2 overexpression in U-251 MG cells stimulated 
migration and invasion [Wang et al., 2012]. EphA3 has also been shown to be elevated in 40% 
of GBM tissues, especially in mesenchymal subtype, and suggested to maintain stem cell 
properties of GSCs and tumorigenicity. Furthermore, EphrinB2 has been suggested to be a 
tumor promoter due to poor survival of patients with high EphrinB2 expression [Nakada et al., 
2010]. Additionally, EphrinA1 stimulation of EphA2 overexpressing GBMs increased 
aggressiveness by enhancing invasive behaviors [Cheng et al., 2002]. In addition to basic 
research for uncovering the roles of Eph/Ephrin system in GBMs, some intervention studies 
have been carried out. For instance, chIIIA4 α-EPHA3 mAb [Day et al., 2013] was used to target 
specifically tumor stroma and inhibited tumor growth by disrupting stromal architecture [Vail 
et al., 2014]. Moreover, EphrinA1-Fc treatment depleted the tumor propagating cell 
population, inhibited self-renewal and induced astroglial differentiation of GBMs [Binda et al., 
2012]. Most of those studies, however, were focused on the intratumoral expression of Eph 
receptors and Ephrins and are limited mostly to Eph receptors and few Ephrin ligands. We still 
have a lot to uncover about the mechanisms and ways of exploitations of Eph/Ephrin systems 
by cancer cells and especially in GBMs. 
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1.2.2. Endothelial Cells and Hypoxic Regions 
Although it is a common phenomenon observed in all solid tumors, glioblastomas are the most 
vascularized ones. This situation is brought about by the vascular proliferation known as 
microvascular hyperplasia which is a hallmark of GBM [Brat et al, 2003]. In microvascular 
hyperplasia, endothelials cells rapidly proliferate forming microaggregates of small blood 
vessels and smooth muscle cells / pericytes called glomeruloid bodies [Brat et al, 2003]. These 
structures differ from the normal blood vessels due to irregular structuring of blood vessels 
within GBM tissue, characterized by dilatations, incomplete or absent basement membranes, 
high permeability, irregular architecture, blind ends, absence of vascular smooth muscle and 
pharmacological / physiological receptors [Vaupel et al, 1989; Vaupel et al, 2004]. 
Caused by the irregularities in the vessel structure and the incomplete (open-end blood 
vesssels) circulation, the oxygen is not delivered homogeneously within the tumor where 
tumor cells spread rapidly going past the diffusion distance of the O2 and nutrients. This 
Figure 3: Bidirectional Clustering of Eph 
receptors and Ephrin Ligands. Upon contact, 
both EPh receptors and Ephrin Ligands 
interact at cis interaction domains (Shown 
by asterisks). Tyrosine phosphorylations are 
shown with yellow circles, Serine 
phosphorylations depicted by orange 
circles. Interation partners are also shown 
[Lisabeth et al., 2013].  
Figure 2: Domains and structure of Eph 
receptors and Ephrin Ligands. EphAs EphBs 
and EphrinBs contain transmembrane 
domains. EphA and EphB contains kinase 
domains as well as some adaptor domains 
where they interach with adaptors of RTK 
signaling pathway [Lisabeth et al., 2013]. 
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situation induces secretion of hypoxia inducible factors which in turn induces angiogenesis 
leading to formation of new blood vessels. However, the newly-formed capillaries will not 
provide enough blood flow for proper distribution of O2 leading to an O2 gradient within the 
neoplasm causing hypoxic or anoxic regions in tumor parenchyma [Vaupel et al, 2004]. The 
severe hypoxic areas frequently delineate the necrotic regions which are another hallmark of 
the solid tumors [Jensen et al, 2009; Heddleston et al, 2010]. The tumor necrosis takes place 
due to increased apoptosis or uncontrolled growth beyond the reach of blood supply [Brat et 
al, 2003]. Interestingly, the tumor size does not play any roles in the degree of intratumoral 
necrosis as it is present in both small and large solid tumors [Jensen et al, 2009]. 
Tumor cells under hypoxia display either a decreased proliferation accompanied by possible 
activation of apoptotic pathways or adaption to the stress which makes them more aggressive 
[Vaupel et al, 2008].  This adaptation towards aggressiveness is mediated by drastic changes 
in the gene expression profile which governs cellular events such as proliferation, glycolysis, 
angiogenesis, metastasis and invasion [Vaupel et al, 2004; Lu et al, 2010; Semenza et al, 2012]. 
In addition to becoming more metastatic and invasive with the alteration of gene expression 
profile upon hypoxia, tumor cells also become more resistant to conventional treatments such 
as chemotherapy and radiotherapy [Semenza et al, 2012]. The resistance to chemotherapy is 
thought to be caused by the decreased potential of cellular proliferation (whereby reducing 
the effectiveness of some chemotherapeutic agents that require cellular proliferation to take 
effect), the reduced activity of chemotherapeutic agents in hypoxic conditions, tissue acidosis 
and/or dampened apoptotic potential of cells [Hockel et al, 2001]. The hypoxia-induced 
radioresistance is proposed to be multi-factorial with decrease of partial oxygen pressure 
being the most likely mechanism followed by the higher levels of heat-shock proteins and 
decrease of apoptotic potential of cells. 
GSCs are located close to the vascular niche of the tumor mass where they intimately interact 
with the endothelial cells and the blood which is reminiscent of normal stem cell behavior 
[Tavazoie et al, 2008]. In fact, the population size of GSCs which are in close contact with the 
blood vessels increases with the grade of the brain tumor which also applies to all GBM cells 
[Calabrese et al, 2007]. Furthermore, GSCs have been shown to travel along the blood vessels 
and transiently pause at vascular branch points for proliferating [Farin et al, 2006]. To further 
support the interaction between GSCs and the endothelial cells, Calabrese et al demonstrated 
the signaling from endothelial cells to GSCs which increased the stem cell – like properties of 
GSCs along with their tumorigenicity [Calabrese et al, 2007]. Nitric oxide (NO) is one of those 
factors capable of enhancing the self-renewal of GSCs in the perivascular niche. NO activates 
Notch signaling in GSCs whereby increasing stem-cell properties of those cells in vitro and 
tumor formation capacities in vivo [Charles et al, 2010]. Moreover, CD133+ BTSCs secrete 
Vascular Endothelial Growth Factor (VEGF) which promotes the formation of new blood vessel 
tubular structure in vitro increasing their tumorigenicity in vivo. In return, endothelial cells 
secrete cues that increase the expression of stem cell markers in GSCs such as Olig2, Bmi1, 
Sox2 and CD133 [Yan et al, 2014]. In the same direction, upon the treatment of mice, which 
have received CD133+ GSCs, with VEGF signaling inhibitor bevacizumab, the tumor growth and 
vascularization slowed down significantly [Bao et al, 2006]. This coupled system forms a 
signaling loop which favors the stem cell – like properties of GBMs and the tumor growth. 
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1.2.3. Immune Cells and Immune Modulatory Cues 
GBMs secrete many cytokines, chemokines and growth factors, which eventually attract many 
other cell types from the vicinity as well as from circulation and promote their infiltration. 
Those cell types include a range of immune cells such as microglia, peripheral macrophages, 
myeloid-derived suppressor cells (MDSC), and regulatory T cells (Tregs) [Fecci et al, 2006; Lohr 
et al, 2011; Alexiou et al, 2013; Wainwright et al, 2013]. Those cells are reprogrammed with 
locally secreted cues thereby acquire new behaviors which either are inflammatory or anti-
inflammatory. Moreover, GBMs, just like other solid tumors, are capable of inhibiting the host 
anti-tumor responses in multiple ways. 
The resident macrophages of the brain are termed microglia. Those cells localize to brain 
during early development and form the ramified microglia thereafter [Hanisch and 
Kettenmann, 2007]. The activity of microglia depends on the type of pathology. In glioma 
microenvironment, microglia are thought to be inactive due to the immunosuppressive 
cytokines secreted by GBM, such as IL-10, IL-6, IL-4, TGF-β and Prostaglandin E2 [Wei et al, 
2010]. Additionally, microglia express low levels of MHC Class II molecule along with some 
other costimulatory molecules [Badie et al, 2002]. When stimulated with lipopolysaccharides 
(LPS) and IFN-γ microglia assume M1 phenotype to secrete pro-inflammatory cytokines such 
as TNF-α, IL-1β and IL-12, present antigen and express high levels of inducible NO (iNOS) for 
NO production. This phenomenon takes place to kill pathogens and induce T cells for adaptive 
immune response [Gordon and Taylor, 2005]. In addition to M1 phenotype, microglia (and 
macrophages) display an M2 phenotype where they express anti-inflammatory cytokines such 
as IL-4, IL-10, IL3 and TGF-β, as well as Arginase-1 (Arg1) and CD206 which then leads to allergy 
response, parasite clearance, inflammatory dampening, tissue remodeling, angiogenesis, 
immune regulation and tumor promotion [Villalta et al., 2009]. In this respect, microglial cells 
seem to acquire M2 phenotype with the increasing histological malignancy. M2 phenotype 
represents the homeostatic state while M1 phenotype is a sign of inflammation. Given these 
facts, in GBM microenvironment, microglia assume an activated morphology but rather a 
different phenotype from that of a regular inflammation [Komohara et al, 2008; Charles et al, 
2011]. Yet, microglia mediate tumor cell migration and tumor growth via MT1-MMP secretion 
in response to cues released from glioma cells, a phenomenon observed only when microglia 
are in the glioma-induced state [Markovic et al, 2005; Sliwa et al, 2007]. However, there are 
two contradictory studies where depletion of microglia, by Markovic et al, resulted in 80% 
decrease in tumor volume, while macrophage depletion, by Gallernau et al, induced 33% 
increase in the tumor volume, showing that myeloid depletion is both pro- and anti-
tumorigenic due to potential unaccounted targeting of additional factors [Markovic et al, 
2009; Galarneau et al, 2007]. 
In addition, Tregs infiltrate the GBM and suppress the immune responses in the GBM via heme 
oxygenase – 1 [El Andaloussi and Lesniak, 2007]. MDSCs inhibit antigen-specific CD8+ T-Cells 
via generation of reactive oxygen species; inhibit T-cell proliferation and promote T-Cell 
apoptosis via nitric oxide synthase (NOS) and arginase-1 (ARG1) generating reactive nitrogen 
species [Marvel et al, 2015]. 
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1.2.4 Astrocytes 
Astrocytes are known for their roles in the maintenance of brain homeostasis as well as the 
blood-brain-barrier where they ensheath the endothelial cells with their end-feet (Kim et al, 
2006). Additionally, they have been implicated in the development of brain tumors where 
reactive astrocytes interact with the brain tumors [Le et al, 2003]. Astrocytes secrete some 
neurotrophic factors such as TGF-α, CXCL12, S1P and GDNF which support the brain tumor cell 
growth [Hoelzinger et al, 2007]. Moreover, cytokines such as TGF-β and IL-6 secreted from 
astrocytes have been shown to promote the tumor cell proliferation in brain, in vitro [Sierra 
et al, 1997]. 
Tumor-associated astrocytes activate a metalloproteinase called proMMP2 aiding the glioma 
cells with their invasion [Le et al, 2003]. SDF1/CXCR-4 signaling is postulated to be an 
important factor in glioma cell proliferation as this signaling pathway is frequently over-
activated in gliomas [Barbero et al, 2002]. Because the astrocytes also secrete SDF-1 [Bajetto 
et al, 1999] they are thought to be involved in the promotion of tumor development. 
Astrocyte elevated gene 1 (AEG-1), which has been demonstrated to be elevated in adult 
astrocytes [Kang et al, 2005], has been implicated in the metastatic progression of brain 
tumors. AEG-1 was found to be frequently overexpressed in brain tumors [Emdad et al., 2007] 
and suppression of AEG-1 hindered the brain tumor growth in mice [Emdad et al., 2010]. 
Additionally, it was shown that, AEG-1 activity requires MMP2 and MMP9 [Emdad et al., 2010; 
Liu et al., 2010]. 
1.2.5. Neural Stem/Precursor Cells 
The neural stem and precursor cells (NPCs) are resident stem cells of the brain which reside in 
subventrical zone and the subgranular zone of the dentate gyrus [Altman and Das, 1967; 
Reynolds and Weiss, 1992; Gage, 2000]. These cells are able to generate many cell types of 
the central nervous system via asymmetric division and differentiation throughout the 
development of the CNS [Reynolds and Weiss, 1992; Cameron et al, 1993]. Additionally, 
neurogenesis in the dentate gyrus is thought to be important for the memory formation and 
functions in the adulthood [Bruel-Jungerman et al., 2007]. 
In the last decade, NPCs have been postulated to be the origin of GBMs. However, the GBMs 
emerge in human brains long after the stem cell activity of NPCs cease. It has been shown by 
many research groups that NPCs migrate towards primary brain tumors and secrete anti-
tumorigenic substances which are beneficial for the overall survival of the patients [Assanah 
et al., 2006; Assanah et al., 2009; Walzlein et al., 2008; Glass et al., 2005]. Stock et al. showed 
in 2012 that, the factors which suppress the brain tumors are endovanilloids [Stock et al., 
2012]. Endovanilloids act on a non-selective cation channel called Transient Receptor 
Potential Vanilloid - 1 (TRPV1) [Stock et al., 2012]. Overall, NPCs in the brain tumor 
microenvironment are beneficial for the treatment and survival. 
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1.3. Mesenchymal Stem Cells in Tumor Microenvironment 
1.3.1. Mesenchymal Stem Cells 
Friedenstein was the first person to describe the multipotential stromal cells in the bone 
marrow where he described the isolation of spindle-shaped, clonogenic cells which he defined 
as colony forming unit fibroblasts (CFU-F). He demonstrated that those cells can be used as 
feeder cells for hematopoietic stem cells (HSC) and in vivo they can differentiate into 
adipocytes, osteocytes and chondrocytes [Friedshein et al, 1976]. Later on, Caplan termed 
those cells as mesenchymal stem cells based on their self-renewal and multilineage 
differentiation capacities [Caplan et al, 1991]. Further research into the biology of those cells 
has shown that, those cells are not only predecessors of cells from mesenchymal lineage, but 
also can transdifferentiate into other embryonic lineages (ectoderm and endoderm) 
[Pittenger et al, 1999]. Although the bone marrow is the place where most MSCs reside, 
research showed that, MSCs are found literally in all postnatal tissues adipose and chondroitin 
being the most well-known tissues [da Silva et al., 2006]. 
 
1.3.2. Defining MSCs 
MSCs can be identified by some visible criteria of proliferation in the in vitro cell culture as an 
adherent population, fibroblast-like morphology (Figure 4), being able to form colonies in 
vitro, and ability to differentiate into three major lineages: osteocytes, chondrocytes and 
adipocytes [Horwitz et al, 2005; Caplan et al, 2011]. In addition to these superficial properties, 
it is possible to define MSC with presence and absence of a series of certain markers as they 
do not possess one unique marker. The consensus is that the human MSCs lack hematopoietic 
markers such as CD45, CD34, CD14 or co-stimulatory ones such as CD80, CD86 and CD40 while 
displaying variable levels of CD105 (endoglin), CD44, CD71 (transferrin receptor), CD73 (ecto-
5’-nucleotidase), CD90 (THY1), CD271 (low-affinity nerve growth factor receptor), and the 
ganglioside GD2 and STRO-1 (anti-STRO1 monoclonal antibody for FACS) [Dominici et al, 
2006]. The variations in the expression levels could be due to species differences, tissue 
sources and culture conditions. 
Upon transplantation, MSCs in the bone marrow, can differentiate into pericytes, 
myofibroblasts, bone-marrow stromal cells, osteocytes, osteoblasts and endothelial cells, 
which all together contribute to the formation of a HSC niche [Muguruma et al, 2006]. The 
MSCs in the HSC niches keep the developing hematopoietic cells in a quiescent stage (at G0 
phase) until a need arises and the signal arrives for them to terminally differentiate and to be 
released to the vascular system [Wilson and Trump, 2006]. In addition, by differentiating into 
osteoblasts and endothelial cells, MSCs shield HCSs from differentiation and/or apoptosis 
signals thereby promoting HSC stemness [Sacchetti et al, 2007]. 
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1.3.3. Roles of MSCs in Homeostasis 
It is well-known that MSCs have profound effects on the immune system and wound healing 
processes [Caplan and Correa, 2011; Bernardo and Fibbe, 2013; Otero-Vinas, 2016]. MSCs 
inhibit T-cell proliferation [Di Nicola et al., 2012], maturation of hematopoietic progenitors 
and monocytes into dendritic cells [Jiang et al., 2005] as well as DC activity [Aggarval et al, 
2005], suppress cytotoxic activity of Natural Killer (NK) cells and interferon (IFN) release 
[Spaggiari et al, 2006]. MSCs coordinate two important phases of wound healing. In the first 
step, the blood-borne molecules leak from blood vessels to the surrounding whereby 
activating MSCs which in turn “turns on” an inflammatory response to clear out potential 
infections. In the second phase, after the infection risk is overcome, MSCs activate the local 
stem cells to promote the scar formation and the tissue healing [Caplan and Correa, 2011; 
Bernardo and Fibbe, 2013; Otero-Vinas, 2016]. 
1.3.4. Tumor-associated MSCs 
The similarity between a tumor and a wound is well established when the damage to the 
surrounding and bleedings are taken into account [Dvorak et al., 1986]. It would be a 
reasonable conclusion if MSCs were assumed to home tumors, just as they home injury sites. 
Wallace et al in 2001, demonstrated the existence of MSCs in the primary tumor site of 
Figure 4: MSCs display fibroblast like morphology with adherent and elongated cell 
structure 
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multiple myeloma [Wallace et al., 2001]. They were located in the perivascular niche of the 
tumor and were morphologically and genetically distinct from tumor cells [Wallace et al., 
2001]. The existence of MSCs was later demonstrated by more research groups in different 
tumors, such as lung, breast and prostate cancers by Gottschling et al, Lamb et al, and 
Santamaria-Martinez et al, respectively [Gottschling et al., 2013; Lamb et al., 2005; 
Santamaria-Martinez et al., 2009]. However, the mechanism by which MSCs migrate and settle 
in tumors has long been a mystery, until when MSCs were shown to migrate upon signaling 
via cytokine/receptor pairs such as SDF-1/CXCR4, SCF-c-Kit, HGF/c-Met, VEGF/VEGFR, 
PDGF/PDGFr, MCP-1/CCR2, and HMGB1/RAGE [Ries et al., 2007; Karp et al., 2009; Baek et al., 
2011; Momin et al., 2010]. Moreover, when the amount of chemokine response elements on 
the surface of MSCs was increased, MSCs displayed an enhanced migration towards tumors 
upon systemic infusion [Shi et al., 2007]. Moreover, in 2009, Kidd et al first demonstrated the 
migration of luciferase-tagged MSCs to breast cancer xenografts upon systemic infusion [Kidd 
et al., 2009]. These phenomena have led to a deeper investigation of MSCs being used as anti-
cancer agent delivery tools. 
In the brain, the presence of MSCs was proven in 2012 by Paul et al, where they characterized 
the adult brain perivascular mesenchymal cells, demonstrating the lack of neural stem cell, 
hematopoietic, endothelial, neuronal and glial markers. Moreover, these cells were able to 
differentiate into cells of mesodermal lineage [Paul et al., 2012]. In terms of brain tumors, 
however, the presence of MSCs has been demonstrated by monitoring the migration of MSCs 
into brain tumors in experimental situations [Birnbaum et al., 2007; Hata et al., 2010; 
Shinojima et al., 2013]. In line with this and the other tumor types, upon flow cytometry 
analyses, GBM biopsies have been shown to contain a vast amount of MSCs, which also brings 
about one of the pathological hallmarks of GBM [Kim et al., 2013; Behnan et al., 2014]. Hossain 
et al. further investigated those MSCs isolated from patient biopsies [Hossain et al., 2016]. 
1.3.5. Role of MSCs in Tumor Niche 
It has been a controversial issue what the role of MSCs in tumor niche is. It was first speculated 
that MSCs invade the tumor sites as there exist incomplete vessels and blood-brain-barrier is 
not intact so the term wounds that do not heal have been introduced for tumors [Dvorak et 
al., 1986] and this situation causes an inflammatory response due to leakage of tumor 
associated molecules into the bloodstream. Additionally, this leakage enables metastatis to 
other parts of the body. Moreover, MSCs take part in the maintenance and growth of the 
perivascular niche. However, soon after the MSCs had been introduced as part of the tumor 
microenvironment, research lead to different findings. It has been demonstrated that, BM-
MSCs promote tumorigenesis of breast cancer stem cells. Throughout their research, Kornaub 
et al found that BM-MSCs increased the migration and invasion capacities of the breast cancer 
stem cells which was brought about by the Chemokine Cytokine Ligand 5 (CCL5) [Kornaub et 
al., 2007]. Additionally, similar effects of MSCs were shown in colon cancer where MSCs 
resulted in an elevated invasive behavior via IL-6 and in prostate cancer where MSCs 
contributed to progression and metastasis via TGF-β [Shinagawa et al., 2010; Lin et al., 2013; 
Ye et al., 2012; Roodhard et al., 2011]. MSCs also caused increased immunosuppression by 
the tumors which eventually lead to increased tumor burden [Djouad et al., 2003]. 
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Furthermore, MSCs resulted in an elevated chemoresistance in breast cancer [Roodhard et al., 
2011]. 
In gliomas, MSCs display profound effects. Glioma stromal mesenchymal stem cells promoted 
increased microvasculature in orthotopic xenografts of GBM thereby increasing angiogenesis 
and aggressiveness [Kong et al., 2013]. Moreover, brain tumor-derived MSCs increase the 
growth of GBMs [Behnan et al., 2014]. Breznik et al showed that BM-MSCs caused an 
increased invasive phenotype of GBM xenografts [Breznik et al., 2017]. Additionally, Hossain 
et al demonstrated that Glioma-Associated MSCs act on GSCs via soluble factors and promote 
tumor growth and aggressiveness [Hossain et al., 2016]. In contrast, MSCs have anti-
tumorigenic effects on GBMs. BM-MSCs mediate anti-angiogenic effects via downregulation 
of PDGF/PDGFR signaling axis [Ho et al., 2013]. Cord blood MSCs upregulate the PTEN in GBM 
cells, leading to a downregulation of PI3K/Akt signaling which in turn inhibits the migration of 
GBMs [Dasari et al., 2010]. Furthermore, amniotic membrane – derived MSCs greatly 
increased the expression of Bax, Caspase 8 and Caspase 3 whereas decreased Bcl2 expression 
thereby inducing the GBM cell apoptosis [Jiao et al., 2012]. 
Consequently, two conflicting roles of MSCs in GBMs proposed by the GBM community: (1) 
MSCs are a possible target for adjuvans treatments of GBM; and (2) MSCs should be exploited 
(to deliver therapeutic means) to cure GBMs. Because of these discrepancies, MSC-related 
therapies are difficult to establish [Mendicino et al., 2014]. In order to overcome these 
problems, it is imperative for MSC research to focus more on the reasons of these variations 
and to shed light on the circumstances under which MSCs are pro- or anti-tumorigenic as well 
as the further signaling pathways which generate those afore-mentioned dichotomous roles. 
Moreover, an enormous proportion of the research about GBM – MSC interaction is limited 
to characterization of soluble factors secreted from MSCs and act on GBMs. When considering 
such paracrine interactions of MSCs, exosomal communication is often overlooked in terms 
of the roles of non-tumor cell exosomes on GBMs [Figueroa et al., 2017]. Therefore, the 
knowledge to be gained from exosomes of MSCs might prove useful in revealing the 
mechanisms of interactions between MSCs and GBMs which in turn might be pivotal for 
understanding the dichotomous roles of MSCs in GBM parenchyma as there would be more 
factors to consider in terms of glioma physiology and pathogenesis. 
1.4. Exosomes 
Cell-to-cell communication has previously been known to be limited to transfer of ions, lipids, 
hormones and proteins from one cell to another by means of extracellular release or via gap 
junctions [Von Euler et al., 1936; Cohen et al., 1954; Brightman et al., 1969; Rodbell et al., 
1980; Fambrough et al., 1999]. In 1981, Trams et al described nano-sized microvesicles and 
posed the term exosomes [Trams et al., 1981]. Their experimental design was for the ecto-5’-
nucleotidase activity of large microvesicles of size 500-1000nm formed by budding from C6- 
rat glioma cells. Through electron microscopy (EM) analyses, they found smaller microvesicles 
which had no ecto-5’-nucleotidase activity and formed in a different pathway from those of 
the larger microvesicles [Trams et al., 1981]. Later, these microvesicles were shown to be 
involved in some physiological processes of reticulocyte maturation [Pan et al., 1983]. Starting 
with those two researches, exosomes have been demonstrated to be important for cellular 
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functions. Recently, a large body of research has built up showing that exosomes carry 
signaling molecules which mediate intercellular signaling [Fevrier et al., 2004; Gyorgy et al., 
2011]. Moreover, those signaling functions are involved in a variety of cell signaling axes such 
as neuron-glia signaling, immune system etc., as well as many pathologies, including cancer, 
which contributes to the complexity of the tumor microenvironment [Fruchbeis et al., 2013; 
Liu et al., 2006; Kim et al., 2006]. 
The term exosome can be confused with the intracellular RNA-degrading exosome complex 
[Mitchell et al., 1997]. However, exosomes are small microvesicles [Johnstone et al, 1987] 
which are 40-100 nm in size and composed of the same lipid bilayer membrane as the cells 
they originate from [Stoorvogel et al., 2002]. This feature makes it possible for exosomes to 
be followed based on the cellular markers they carry. Additionally, knowing the biogenesis of 
exosomes might shed light on their composition, possible functions and ways of intervention 
for therapeutic purposes. 
Exosomes are thought to be derived from endosomal compartment although, in T Cells, they 
were demonstrated to be developed by direct budding from the plasma membrane [Booth et 
al., 2006]. Endosomal system is responsible for the intracellular protein trafficking between 
cellular organelles and plasma membrane. During endocytosis, early endosome forms via 
internal budding of the plasma membrane. As part of the maturation process of early 
endosomes into late endosomes, intraluminal vesicles (ILVs) form within the lumen of the late 
endosomes, which are then, therefore, called multivesicular bodies (MVBs). ILVs are the 
potential predecessors of exosomes. During this process, the contents fated to be degraded 
or exported are sorted into 40-100 nm sized ILVs. MVBs then can either fuse with lysosome 
for degradation of the contents or can merge back with the plasma membrane for secretion 
of vesicular contents. [Buschow et al., 2009]. Those released microvesicles are called 
exosomes (Cocucci et al., 2009). The fusion of MVBs with the plasma membrane and thereby 
the release of exosomes is an energy-dependent process which also utilizes calcium signaling 
similar to neurons releasing the packaged neurotransmitters into the axonal cleft (Figure 5) 
[Savina et al., 2003; Savina et al., 2005]. The exosomes, after being released, have similar 
protein characteristics to the original cell as well as signaling molecules packed in them and 
can go interact with the target cells upon which they deposit their internal cargo [Thery et al., 
2002]. 
Even though the cellular membrane and the exosomal membrane are similar in content, they 
are never the same e.g. exosomes lack various cluster of differentiation (CD) and fragment 
crystallizable (Fc) antigens as well as some integrins that are present on the plasma membrane 
[Thery et al., 2001]. This shows that, during the channeling of internal budding of the 
endosomal membrane to form ILVs, some of the proteins are removed or concentrated on the 
membranes of the future-exosomes. The re-modulation of the membrane content of 
exosomes is not limited to proteins, but also lipids are subject to removal or concentration 
[Thery et al., 2001]. For instance, exosomes contain higher levels of ceramide, a lipid with 
signaling properties [Trajkovic et al., 2008], cholesterol and phospatidic acid (PA) [Laulagnier 
et al., 2004]. 
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A greatly important process is the sorting of the EV cargo during internal budding of the 
membrane which leads to ILV formation. The endosomal-sorting complex required for 
transport (ESCRT) mediates the accumulation and sorting of molecules packed into the ILVs as 
well as the remodeling of vesicular membranes (Morvan et al., 2012; Adell et al., 2014].  
Perturbation of this system leads to defects in the exosomal protein content and the rate of 
exosome release [Colombo et al., 2013]. Moreover, the process can be adjusted based on the 
type of the cell and the needs of the cell. For instance, specific RNA-binding ribonucleoproteins 
(RNPs) on exosomal membranes recognize specific nucleotide sequences on RNAs thereby 
binding to them as they bud inwards in the late endosome. Which RNAs are packed into the 
exosomes can be determined by the RNPs. Additionally, reports indicate that, the process of 
packaging the exosomal cargo involves sphingomyelinase [Laulagnier et al., 2004], Syndecan-
Synthenin interaction [Baietti et al., 2012], GTP-binding protein, ADP-ribosyylation factor 6 
(ARF6) and its effector Phospholipase D2 (PLD2) [Ghossoub et al., 2014]. At the final stage, 
where exosomes are released, Rab family of small GTPases [Stenmark et al., 2009; Tauro et 
al., 2013] and the soluble NSF-attachment protein receptor (SNARE) complex [Fader et al., 
2009] have been implicated to play a role. 
Figure 5: Formation of exosomes. Endocytosis leads to formation of early endosomes (EE). 
With inward budding of the multi-vesicular body (MVB), intraluminal vesicles (ILV) form. 
ILVs are packaged with proteins, RNAs, membrane bound receptors, etc. Finally, the MVB 
fuses with the plasma membrane to release the ILVs as exosomes packaged with relevant 
signaling molecules. During the packaging of ILVs, ESCRT complexes I, II and III take part, 
and the exocytosis is mediated by the interplay of Rab GTPases and SNARE complex 
(Bellingham et al., 2012).  
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The exosome content is highly heterogeneous as they may contain proteins, nucleic acids 
(RNAs such as mRNA and miRNA, DNA) and lipids. Moreover, the protein content of the 
exosomes is not only the intravesicular proteins but also the surface molecules [D’Asti et al., 
2012]. The exosome cargo is precisely modulated by an interplay of a variety of regulatory 
mechanisms governing the type and physiological condition of the donor cell, the stimuli 
causing the exosome production and the pathways leading to production of different exosome 
types [Minciacchi et al., 2015]. Those processes also make the exosome function broad, based 
on the contents. Exosomes contain integrins which are important for the interactions with 
extracellular matrix (ECM) and for the interaction with the recipient cell, leading to 
internalization [Rieu et al., 2000; Ngora et al., 2012]. Moreover, major histocompatibility 
complexes (MHC) have been shown to be present on exosomal membranes where they can 
contribute to antigen presentation in case of an infection or a cancer [Testa et al., 2010; Yang 
et al., 2012]. Some other proteins such as Alix, Tsg101, flotillin, Rab, and tetraspanin family 
members of proteins are found on exosomes and are also used as exosome markers. Those 
proteins are also involved in exosome biogenesis [Colombo et al., 2013; Romancino et al., 
2013; Trajkovic et al., 2008; Savina et al., 2002; Ostrowski et al., 2010]. Among those 
tetraspanins, especially CD9, CD63 and CD81 have been shown to be involved in the 
endosomal vesicle trafficking (Figure 6) [Pols and Klumperman, 2009; Abache et al., 2007]. 
Intracellular compartment of the exosomes also contains multiple proteins and functional 
genetic elements (Figure 6). The proteins are packaged via the interactions with the exosome 
biogenesis machinery [Biaetti et al., 2012]. Additionally, tetraspanins interact with the 
membrane proteins in a direct manner or via entrapment into tetraspanin microdomains 
mediate their loading into the exosomes [Mazurov et al., 2013]. The protein content in the 
intravesicular compartment is mostly dependent on the cell of origin, however, 
glyceraldehyde-3-phosphate dehydrogenase have been shown to be included in many types 
of exosomes which points out for a role for exosomes in metabolism [Tisdale et al., 2001; 
Ronquist et al., 2013]. Apart from proteins, exosomes were shown to harbor RNAs and 
transfer them between cells [Ratajczak et al., 2006]. Subsequently, it was demonstrated that 
the mRNA transferred from one cell to another via exosomes can be translated into protein 
[Valadi et al., 2007]. Moreover, exosomes released from malignant tumors have been shown 
to transfer a malignant phenotype to formerly less aggressive tumors [Zomer et al., 2015]. 
Apart from the mRNAs, exosomes also are rich in small non-coding RNA species through which 
they function to modulate the gene expression in the recipient cells [Baglio et al., 2015; 
Koppers-Lalic et al., 2014]. Those small non-coding RNAs consists mostly of miRNAs which 
regulate the gene expression at the post transcriptional level in the recipient cell upon transfer 
via exosomes (Figure 5). They bind to the 3’ UTR regions of the mRNAs and either direct them 
to degradation or prevent their translation by staying bound to the mRNA thereby causing 
abortion of translation by the ribosomal machinery. Evidence suggested that oncogenic 
miRNA transfer from one tumor cells to a healthy cell causes a malignant transformation 
whereas, tumor-suppressive miRNA transfer into a tumor cell caused regression of tumor 
properties [Aucher et al., 2013; Kruger et al., 2014]. Whether specific miRNAs are loaded into 
exosomes and if so, what mediates the selective loading of these miRNAs, however, is still 
unclear. It is important to uncover the contents of exosomes in order to reveal their true roles 
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in the cellular and tumor biology. Therefore, the accumulating research findings have been 
compiled into online databases which are available for scientific use. Those databases are: 
Exocarta, Vesiclepedia and EVpedia [Mathivanan et al., 2009; Kalra et al., 2012; Kim et al., 
2013]. 
 
 
 
Exosomes interact with the recipient cell in four different defined ways: direct fusion and 
deposition of the contents into the recipient cell, receptor-mediated internalization (upon 
receptor interaction on plasma membrane or on lipid rafts), receptor activation via interaction 
of exosome membrane-bound ligand with a receptor on the cell surface of the recipient cell 
and antigen presentation which mostly occurs in the immune system (Figure 7) [Denzer et al., 
200; Thery et al.,2011]. As mentioned above, exosomal membranes contain specific proteins. 
Those proteins direct exosomes to certain cell types by acting as interaction partners for the 
proteins on the recipient cells. This means exosomes are not randomly taken up by any cell in 
miRNAs 
mRNAs 
mRNA 
miRNA 
Figure 6: Structure and the cargo of an exosome. Exosomal cargo includes many 
membrane-bound proteins such as tetraspanins, target cell recognition antigens, adhesion 
molecules, as well as intravesicular elements involved in cargo packaging and mRNAs, 
miRNAs and enzymes [image modified from Mathivanan et al., 2010]. 
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the vicinity, but in fact they are destined to specific cell types, which adds up into the 
complexity of exosome biology. Upon interaction of the exosome-surface proteins with the 
recipient cell-surface proteins, exosomes either release their contents into the cytosol of the 
recipient cell or are taken up via receptor-mediated endocytosis. In both cases, the exosomal 
membranes, and so the proteins, are integrated into the membrane of the recipient cell. 
However, the exosomes which are taken up via receptor-mediated endocytosis sometimes 
might be targeted for degradation. That is why, only the exosomes escaping those degradation 
processes can mediate an effect in the recipient cell [Svensson et al., 2003; Prada and 
Meldolesi et al., 2016]. 
 
 
 
Figure 7: Exosomes interact with the target cells in several ways. They can (I) act for antigen 
presentation in the immune system, (II) activate cell surface receptors on the recipient cell 
by the binding of the membrane-bound ligands on exosomes, (III) be taken up by 
endocytosis and (IV) fuse directly with the plasma membrane of the recipient cell 
depositing the contents into the cytosol [Krause et al., 2015]. 
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1.5. Gliomas and Exosomes 
Exosomes were first identified in cancer, and subsequently, researchers invested large efforts 
into uncovering the roles of exosomes in cancer research.  Within various experimental 
settings, researchers defined many roles for exosomes in cancer. For instance, exosomes from 
melanomas induce molecular alterations in the malignant tumor cells thereby mobilizing them 
to leave the initial tumor location, which in turn contributes to metastatic dissemination. 
Additionally, those exosomes prepare a metastatic target niche in the sentinel lymph node for 
those mobile cells by increasing the production of ECM components. Exosomes also stimulate 
proangiogenic factors which eventually results in nodal metastases (Hood et al., 2011). 
Moreover, exosomes decrease the immune surveillance via enhancing the levels of 
immunosuppressive cells, decreasing the proliferative capacity and cytotoxic properties of NK 
and T Cells as well as the number and function of APCs [Zhang et al. 2011; Zhang et al., 2012]. 
Last but not least, exosomes are utilized as mechanisms of chemoresistance in tumors where 
they are packed with the chemotherapeutic agent and exported out of the cell which is called 
vesicle shedding [Shedden et al., 2003]. In contrast to those findings in tumors, less extensive 
research has been done on gliomas. 
The exosomes in the normal brain are released both by neurons and glia to rapidly signal 
between each other to mediate protective effects against stress, to promote repair, survival 
and immunity as well as synapse and plasticity formation [Budnik et al., 2016]. In brain tumors, 
those properties of exosomes are hijacked in order to increase the growth and adapt to 
changes in the microenvironment. The exosomes released from GBMs have been shown to 
include mRNAs and miRNAs [Skog et al., 2008]. Those RNA species are selectively packaged 
into exosomes, as opposed to the parental cell, for specific purposes based on the conditions 
[Li et al., 2013]. In line with this, glioma cells under hypoxic conditions have been shown to 
increase the hypoxia-related mRNA and protein content in exosomes they released 
[Kucharzewska et al., 2013]. Moreover, GBM-derived exosomes have been demonstrated to 
contain oncogene protein products such as epidermal growth factor receptor variant III 
(EGFRvIII). This growth factor receptor is constitutively active and accumulates on the lipid 
rafts of the recipient cells, where it starts a signaling cascade to eventually alter the gene 
functions related to the growth via ERK1 – ERK2 and AKT pathways [Al-Nedawi et al., 2008]. 
Treps et al showed that, exosomes also transfer the vascular permeability factor Semaphorin 
3A to the adjacent endothelial cells which elevates the vascular permeability favoring the 
tumor angiogenesis [Treps et al., 2016]. Furthermore, GSC-derived exosomes contain TGF-β 
which inhibits the immune response of the recipient immune cells in the vicinity such as 
microglia and macrophages/monocytes by altering their cytokine expression profile [Graner 
et al., 2009]. The exosomes, however, not only contain pro-tumorigenic elements but also 
may contain anti-tumorigenic species such as miR-1. miR-1 targets Annexin – A2 mRNA, which 
is one of the most abundant mRNAs in the GBM-derived exosomes and whose protein product 
is pro-ongogenic [Bronisz et al., 2014]. 
The findings of the exosome studies have been used for further translational research. Wolfers 
et al demonstrated that the glioma-derived exosomes carry antigens specific to the tumor. 
Those exosomes were then used to potentiate dendritic cells which in turn activated T-cells 
causing a massive cytotoxicity [Wolfers et al., 2001]. This discovery made the researchers 
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question if tumor-derived exosomes could be used as vaccines to immunize the patients. 
However, there has been some adverse effects reported regarding the use of exosomes in 
tumor therapy [Zhang et al., 2011; Zhang et al., 2013]. Additionally, it was shown that, upon 
treatment with ionizing radiation, glioma exosomes gain increased levels of some growth 
factors and growth factor receptors. Those exosomes then induced activation of tyrosine 
kinase receptor type 1 (TrkA) and a well-known proto-oncogene Src kinase in non-irradiated 
glioma which altogether lead to an increase in the migration and invasion showing that 
irradiating gliomas cause enhanced migration and invasion of the surrounding tissue by the 
non-irradiated cells of the tumor [Arscott et al., 2013]. As for the diagnostic purposes, Skog et 
al demonstrated that, GBM patient sera contained EGFRvIII mRNA and miR-21 in the 
exosomes as opposed to those from the healthy donor sera. This finding then brought the 
notion that the circulating exosomes could be used to identify the mutation status as well as 
the gene expression profile of the brain tumors [Skog et al., 2008]. However, the available 
miRNA copy numbers were relatively low, making the analysis difficult. Akers et al then 
demonstrated that the spinal fluid could be used for the same purpose where the copy 
numbers are high enough for further analyses [Akers et al., 2015]. All in all, the fact that the 
exosomes in the bodily fluids could be used for diagnostic purposes for brain tumors have 
been speculated as a promising tool, because they can be easily collected without any invasive 
procedures as in biopsies; they contain valuable information regarding the genetic status of 
the tumor cell they originate from; and the half-life of them are short in the body fluids which 
can be an advantage for monitoring the short-term changes in the tumor cells [André-Grégoire 
et al., 2017]. 
Exosomes have been also exploited to deliver anti-tumorigenic species into the tumor tissues 
because they can travel through body fluids, cross membranous structures such as BBB and 
easily access the brain. In one study, exosomes were made to contain a peptide on their 
surface which can bind to EGFR. Those exosomes were packed with let-7a miRNA targeting 
EGFR and administered intravenously in an EGFR-expressing breast cancer model. Exosomes 
were shown to reach the tumor cells and inhibit tumor growth [Ohno et al., 2013]. In another 
study, exosomes were shown to reach the brain via intranasal application. Moreover, 
exosomes that were packed with curcumin had significant effects on the delay of the tumor 
growth in GL261 mouse tumor model [Zhuang et al., 2011]. Moreover, exosomes have been 
engineered to deliver synthetic vectors, viral Exosomes, therefore, could be utilized as vehicles 
to deliver anti-tumorigenic agents into tumor cells upon engineering for specific purposes. 
1.6. MSCs, Exosomes and Tumors 
Exosome research in the context of tumors, and specifically gliomas, have mostly focused on 
the tumor derived exosomes. However, tumors are complex structures that are in close 
relationship with the microenvironment. Therefore, it is imperative to uncover the effects of 
the exosomes from the vicinity on gliomas. There are many cell types in the tumor 
microenvironment, some of which have been explained above in the context of brain tumors. 
One cell type proven to be important, which is also the main focus of the thesis, is the MSCs. 
MSCs have been implicated in studies regarding exosomes in the context of tumor. BMSCs 
have been shown to contain, in addition to classical exosome markers such as Alix, Tsg101, 
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CD9, CD63 and CD81, PDGFR-β, TIMP-1 and TIMP-2 which support tumor growth 
[Vallabhaneni et al., 2015]. Additionally, some proteins which are implicated in the packaging 
and transport of RNA, such as argonaute 2, Staufen1 (Stau1) and Staufen2 (Stau2), have been 
shown to be present in the exosomes of MSCs [Collino et al., 2010]. Moreover, some proteins 
which promote angiogenesis via Wnt – β-catenin pathway are also carried in the exosomes 
derived from MSCs [Chen et al., 2014]. In addition to those protein cargos, exosomes from 
MSCs carry also mRNAs whose protein products are implicated in the control of cytoskeletal 
reorganization, regulation of transcription, cell immunity and differentiation as well as 
proliferation and cellular growth [Bruno et al., 2009; Tomasoni et al., 2013]. Moreover, some 
miRNAs in the form of pri-miRNAs are present in MSC-derived exosomes some of which are 
related to promoting cellular growth and preventing apoptosis [Katakowski et al., 2013] as 
well as decreasing tumor growth [Xin et al., 2013]. 
As a result of the identification of exosome cargos of MSCs, they have been identified as 
important contributors of tumor pathology in the microenvironment. In addition to 
previously-mentioned pro- or anti-tumorigenic effects on tumors that are mediated via 
secreted species or direct contact, MSCs also have been shown to exert profound effects on 
tumors via their exosomes. It was shown that, MSC-derived exosomes increase VEGF 
expression which in turn favors the tumor growth via ERK1/2 and p38-MAPK pathway. This 
situation was reversed by ERK1/2 inhibition [Zhu et al., 2012]. Moreover, MSC-exosomes 
promoted metastasis, proliferation and survival of myeloma cells by influencing the activities 
of p38, p53, c-Jun N-terminal kinase and Akt pathways [Wang et al., 2014]. Yang et al 
demonstrated that the stimulated via MSC-derived exosomes, tumors gain new cellular 
dynamics which are beneficial for the re-organization of the microenvironment [Yang et al., 
2015]. Interestingly, those exosomes of MSCs demonstrated the capability of transferring 
mRNA for a growth factor into tumor cells where it induced ERK1/2 – MAPK pathways thereby 
promoting the transition of cell cycle from G0/G1 to S phase [Du et al., 2014]. MSC exosomes 
not only enhance tumor growth but also promote chemoresistance. MSC-exosomes have 
been shown to boost resistance against bortezomib used in multiple myeloma treatment 
[Wang et al., 2014] by preventing apoptosis [Ono et al., 2014]. 
Contrary to those pro-tumorigenic properties, MSC-derived exosomes have anti-tumorigenic 
effects too. They block tumorigenesis by preventing the cell cycle progression in 
hepatocellular carcinoma, Kaposi’s sarcoma and a type of ovarian cancer by upregulating 
expression of some genes which favor a dormant cell state. They also induced apoptosis in 
Kaposi’s Sarcoma and hepatocellular carcinoma cells [Bruno et al., 2013]. Moreover, 
exosomes from MSCs blocked the expression of VEGF in mouse breast cancer cells thereby 
inhibiting angiogenesis [Lee et al., 2013]. The mechanisms of antitumor capabilities of MSC – 
derived exosomes have not yet been fully characterized, therefore contains large gaps in the 
information pool. And in terms of MSC-exosomes and glioma interaction, there isn’t a large 
body of research. Recently, Figueroa et al demonstrated that, Glioma-associated exosomes 
increase the proliferation and clonogenicity of GSCs and carry miR-1587 which inhibit nuclear 
receptor co-repressor 1 (NCOR1), a tumor suppressor [Figueroa et al., 2017]. Moreover, 
Munoz et al utilized MSCs as delivery vectors for anti-miR-9 whose transfer was mainly 
achieved via exosomes. They demonstrated the chemosensitization of GBMs by inhibiting 
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miR-9 which is important for acquisition of resistance to TMZ by being involved in the 
expression of P-glycoprotein, a drug efflux transporter [Munoz et al., 2013]. One interesting 
study utilized the intratumoral injection of exosomes from miR-146 expressing MSCs. In this 
setting, exosome-laden miR-146 inhibited translation of EGFR reducing growth and invasion 
capacities [Katakowski et al., 2013]. In addition, GBM-derived exosomes have effects on MSCs 
as well [Chowdhury et al., 2015] making the interaction between MSCs, the exosomes 
released from MSCs and the GBMs very complex. 
1.7. Summary 
All in all, gliomas are therapy-resistant, highly aggressive and deadly cases. One major cause 
of the incurability is brought about by the intimate relationship of glioma cells with the tumor 
microenvironment, which supports the tumor growth in many ways by providing a permissive 
neighborhood. In the tumor microenvironment are BTSCs, ECs and hypoxic regions, immune 
cells and immune modulatory cues, astrocytes, neural stem/precursor cells and MSCs. 
Different cell types contribute to tumor pathology in different ways. One eminent and not-
yet-fully-explored interaction is the one between MSCs and GBMs. MSCs have pro-and anti-
tumorigenic effects on GBMs and the quality of this interaction is dependent on the source of 
MSCs and the way interaction takes place. Exosomes are minute vesicles carrying signaling 
materials which are secreted by many cell types in the tumor microenvironment. However, 
exosomes from GBM cells and the MSCs are of utmost importance as the tumor-derived 
exosomes hijack the surrounding to permit growth of the tumor and MSC-derived exosomes 
mediate supportive or suppressive effects on tumors. While the latter case has not been 
explored very deeply, the effects of tumor-derived exosomes on the microenvironment are 
well-established. That is why, it is vital to shed light on the interaction mechanisms of MSCs 
and MSC-derived exosomes with GBMs, which may support therapeutic approaches by 
providing a novel treatment target. Furthermore, it might be a base for further studies which 
utilize MSCs or MSC-derived exosomes as vectors for tumor therapy. 
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2. AIM OF THE THESIS 
MSCs have been shown to be at the interplay of many pathologies including cancer 
(Gottschling et al., 2013; Lamb et al., 2005; Santamaria-Martinez et al., 2009; Wallace et al., 
2001; Dvorak et al., 1986). Although certain roles have been assigned to MSCs about their 
homing behavior to cancers in general, the studies as to what roles MSCs play in the brain 
tumor niche are very few. Moreover, the interaction between MSCs and the GBM cells is 
claimed to be both pro-tumorigenic and anti-tumorigenic, and under what circumstances they 
behave one way or another is largely unexplored. Therefore, shedding light on this interaction 
might prove beneficial for developing treatment strategies against these devastating 
disorders. 
The aim of this study was to explore the mode of interaction between MSCs and GBMs, and 
to determine relevant signaling pathways. 
Specific questions are: 
1. Under what circumstances do MSCs act as pro- or anti-tumorigenic? 
2. Are pro- or anti-tumorigenic conditions more relevant to the in vivo interaction 
between MSCs and GBMs? 
3. What pro-tumorigenic impacts do MSCs have on GBMs? 
4. What are the modes of signaling between MSCs and GBMs mediating either pro- or 
anti-tumorigenic effects? 
5. What signaling molecules are involved in pro-tumorigenic pathways induced in GBMs 
by MSCs? 
6. Do MSCs render GBMs chemoresistant? What molecules take part in chemoresistance 
induction? 
7. Can we generate a universal mouse model to study the interaction of MSCs with 
various GBM subtypes for in vivo? 
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3. MATERIALS AND METHODS 
3.1 List of Some Basic Materials 
 
3.1.1. Cell Culture Contents 
Material Supplier Cat # 
Dulbecco’s Modified Essential Medium (DMEM) Biochrom GmbH FG0415 
DMEM F/12 Thermo Fischer 
Scientific 
11320033 
NeuroCultTM Basal Medium Stemcell Technologies 05700 
Roswell Park Memorial Institute Medium (RPMI) Thermofischer 
Scientific 
11875093 
NeuroCultTM Proliferation Supplement Stemcell Technologies 05701 
Fetal Calf Serum (FCS) Thermofischer 
Scientific 
10270106 
B27 Thermo Fischer 
Scientific 
17504044 
Minimal Essential Medium Non-essential Aminoacids 
(MEM NEAA) 
Thermo Fischer 
Scientific 
11140068 
Pen/Strep Thermo Fischer 
Scientific 
15140122 
hEGF Thermo Fischer 
Scientific 
PHG6045 
FGF Thermo Fischer 
Scientific 
PHG0263 
Trypsin Biochrom GmbH L 2123 
Accutase Stem Cell 
Technologies 
07920 
 
3.1.2. Cell Culture Materials 
Material Supplier Cat # 
Cell Culture Flasks (T25; T75; 
T150) 
TPP 90026; 90076;90156 
Well-Plates (96, 24, 12, 6) TPP 92696; 92424; 92412; 92406 
Falcon Tubes (15 ml; 50 ml) TPP 91015, 91051 
Microfuge Tubes Eppendorf T9661-1000EA 
Countess II FL Thermo Fischer Scientific  
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3.1.3. Reagents Purchased 
 
3.2 TaqMan Assays 
3.2.1 QKIs (Thermo Fisher Scientific) 
QKI-5: Hs00916681 (RefSeq: NM 006775.2) 
QKI-7: Hs00920546 (RefSeq: NM 206854.2) 
QKI-general: Hs00916678 (RefSeqs: NM 006775.2; NM 206853.2; NM 206854.2) 
For Calculation of QKI-6 amounts, I subtracted the amounts of QKI-5 and QKI-7 from QKI-
general results. 
3.1.2. EFNA3 
EFNA3: Mm01212723_g1 (RefSeq: NM_010108.1) 
3.3. Vectors for Overexpression and Knockdown 
Overexpression and knockdown vectors were all purchased from BioCat. 
3.3.1. Knockdown 
QKI: TLHSU1400-9444-pZIP-mCMV-ZsGreen-GVO-TRI 
EFNA3: TLMSU1400-13638-pZIP-mCMV-ZsGreen-GVO-TRI 
Non-targeting Control: TLNSU-1400-GVO-TRI 
3.3.2. Overexpression 
QKI-5: RC205779-OR 
QKI-6: RC224090-OR 
QKI-7: RC215734-OR 
EFNA3: BC107002-TCM1004-GVO-TRI 
 
 
Material Supplier Cat # 
Non-Radioactive Cell 
Viability/Proliferation Assay 
Promega G4100 
Temozolomide (TMZ) Sigma Aldrich T2577 
QuantiTect Reverse 
Transcriptase 
Qiagen 205310 
RNeasy RNA Isolation Kit Qiagen 74106 
ExoQuick-TCTM Exosome 
Isolation Kit 
System Biosciences EXOTC50A-1 
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27 
 
3.4. Cell Culture 
 
3.4.1. MSC Cell Culture 
Bone marrow derived MSCs were purchased from Thermofischer Scientific (Cat. #: S1502100) 
and cultured according to manufacturer’s instructions. Briefly: MSCs were maintained in 
Dulbecco’s Minimum Essential Medium (DMEM – Biochrom, Cat #: FG0415) supplied with 20% 
FCS (Thermofischer Scientific - 10270106), 1% MEM NEAA (Thermo Fischer Scientific – Cat #: 
17504044) and 1% Pen/Strep (Thermo Fischer Scientific – Cat #: 15140122) with a seeding 
density of 300,000 cells/150 cm2 and grown at 37 ˚C under 5% CO2/95% humidified air. While 
passaging, 20% FCS medium is discarded and the cells were washed with PBS of appropriate 
volume based on the size of the culturing flask (3 ml for T25; 6 ml for T75 and 10 ml for T150) 
and trypsin (Biochrom GmbH – Cat #: L 2123) is added again based on the size of the culturing 
flask (1,5 ml for T25; 3 ml for T75 and 6 ml for T150) and the flask is incubated for 3-5 mins at 
37 ˚C until the cells dissociate. The trypsin is then inactivated by addition of DMEM containing 
20% FCS and the MSCs are split. The passaging is carried out every 2 days. 
 
 
 
Medium Cell Line 
 
 
 
 
 
DMEM F/12 with B27 (1X), Pen/Strep (1%), human Embryonic 
Growth Factor (hEGF) and Fibroblast Growth Factor (FGF). (10 
ng/ml each) 
GBM10 
GBM13 
GBM14 
GBM20 
NCH588J 
NCH684 
NCH421k 
NCH644 
NCH592b 
P53KO-PDGFB-GFP 
 
 
NeuroCultTM Basal Medium supplied with NeuroCultTM 
Proliferation Supplement, Pen/Strep, hEGF and FGF (10 ng/ml 
each) 
Line 4 
Line 6 
Line 7 
Line 8 
Line 9 
Line 11 
DMEM, supplied with 20% FCS, MEM NEAA (1%) and Pen/Strep 
(1%) 
MSC 
RPMI supplied with 10% FCS and Pen/Strep (1%) HEK293 
DMEM, supplied with 10% FCS, MEM NEAA (1%), Pen/Strep (1%) HEK293T 
GL261 
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3.4.2. GSC Cell Culture 
GSC primary cultures were kept either in DMEM/F-12 or NeuroCultTM Basal Medium (mouse). 
Both cultures were maintained at 37 ˚C under 5% CO2/95% humidified air. GSCs grow in form 
of spheroids. When passaging, GSC cell suspension is taken into falcon tubes and centrifuged 
at 400xg for 5 mins. The supernatant is discarded and the spheroids are either resuspended 
in 1 ml of fresh culture medium and dissociated with rigorous pipetting with a 1 ml – 
micropipette or when the spheroids are firm, they are resuspended in 1 ml of accutase, a cell 
detachment solution (Stem Cell Technologies – Cat #: 07920), and dissociated with rigorous 
pipetting with 1 ml – micropipette. When accutase is used, the GSCs are washed with addition 
of 9 ml of cell culture medium and additional centrifugation of 5 mins at 400xg. The 
supernatant is discarded and the GSCs are split at an appropriate seeding density specific for 
each GSC line determined based on their growth rate. The passaging is carried out every 3 
days. All GSCs were maintained in normal cell culture flasks, except p53KO-PDGFB-GFP, which 
was cultivated in normal microbiology-grade petri dishes due to high potential of adherence 
and differentiation in coated cell culture dishes. 
3.4.3. HEK293 Cell Culture 
HEK293 cells were cultivated in RPMI (Thermofischer Scientific, Cat #: 11875093) supplied 
with 10% FCS, 1% MEM NEAA and 1% Pen/Strep. These cells are also adherent, similar to 
MSCs, so the passaging protocol was the same as that of MSCs. 
3.4.4. Freezing Medium 
In order to keep stocks of low passage cells, I froze aliquots at low passages at -80 ˚C until they 
were needed. For this, I used a special type of medium for different cell types. For GSCs, it 
included (at final mixture with cells included) 5% DMSO in DMEM/F-12 without additives. For 
MSCs, it included (at final mixture with cells included) 5% DMSO and 10% FCS in DMEM. The 
concentration of DMSO and FCS were double in the stock solutions of freezing medium. When 
I freeze cells, I mix 500 µl of cell suspension in respective medium (without additives) with 500 
µl of the appropriate freezing medium. The cells were then placed into isopropanol-
submerged cryovial holders and placed into -80 ˚C for overnight. Then cryovials were taken 
into liquid nitrogen tank for long term storage. 
3.4.5. Cell Counting 
I counted cells throughout my experiments both manually and with a cell counter. For the 
manual cell counting, I centrifuged the cells and discarded the supernatant. Then I 
resuspended the cells in 1 ml of culture medium, mixed 20 µl of cell suspension with 20 µl of 
trypan blue and placed approximately 20 µl of the mixture into cell counting grid (Neubauer). 
For the automated cell counting, I used the same cell suspension – trypan blue mixture with a 
special counting grid and inserted the grid into counting machine (Countess II FL from Thermo 
Fischer Scientific). This device counts the cells and calculates the amounts of cells in 1 ml of 
medium. 
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3.5. Conditioned Medium (CM) 
MSCs were plated in dishes with 150 cm2 culturing area at a density of 300,000 cells per dish 
and maintained in normal culturing conditions (DMEM with 20% FCS) at 37 ˚C under 5% 
CO2/95% humidified air. After 2 days when they reached a near-confluent stage, the growth 
medium was discarded, the cells were washed with a large amount of PBS (20 ml) and DMEM 
with no FCS (but 1% Pen/Strep and MEM NEAA) was added. After cultivating for 72 hours, the 
suspension medium was harvested by centrifuging the cells and cell debris at 3000xg for 15 
mins and filtering with a pore size of 0.45 µm. 
3.6. Viability Assay 
Non-Radioactive Cell Viability/Proliferation Assay was purchased from Promega (Cat #: G4100) 
and applied based on manufacturer’s instructions. Briefly: 7,000 cells were plated in each well 
of a 96-well plate (5 replicates for each condition and for each cell line used), either with CM 
or with control (DMEM without FCS) for 72 hours. On day 3, pictures of the cells in each well 
were taken for additional analyses. Then dye solution from the viability assay was added, 15 
µl in each well and the plates were incubated at 37 ˚C under 5% CO2/95% humidified air for 4 
hours. Then, stop/dissociation solution of 100 µl was added in each well to stop the assay, 
disrupt the cells and dissolve the purple oxalate crystals formed within the cells to produce a 
colored solution. The plates are then incubated again in the same incubation conditions as 
before for 1 hour. The colorimetric absorbance was then measured by elisa reader aided by a 
computer. The background-subtracted absorbance values are then analyzed using Nalimov’s 
Test in order to determine the outliers. The absorbance of the control cells (cells maintained 
in normal cell culture medium, DMEM) were averaged (from 5 replicates) and the average 
value was arbitrarily set as 1. The same averaging was performed for experimental conditions 
and they were normalized to the average of control cells. The values were then plotted as bar 
graphs. 
3.7. Chemoresistance Assay 
TMZ (25 mg) was dissolved initially in 644 µl of DMSO and then further dissolved in DMEM to 
reach 200 mM stock solution in order to prevent DMSO cytotoxicity. From that stock it was 
diluted to 100 µM or 300 µM either in DMEM or CM. 
In a 6-well plate format, 100,000 cells per well with 3 replicates of DMEM (Control) or CM with 
100 or 300 µM TMZ in DMEM or CM were plated. For the consecutive days, the media in each 
well was replaced with fresh media with or without TMZ in DMEM or CM. After 3 days of TMZ 
treatment, the cells were moved into their regular culturing medium. On day 7, the cells were 
counted and 100,000 cells were plated back for counting on day 14. On day 14, the same way, 
cells were counted and 100,000 cells were plated again. On day 21 the final count was 
performed and cells were discarded (For an illustration of the method applied, see the figure 
below). The calculation was performed based on the total amount of cells on each counting 
day, i.e. 100,000 cells were plated back but the calculation was made based on the total 
number of cells counted on that specific day. The results were then plotted. 
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3.8. Exosome Isolation and Depletion 
Exosomes were isolated via ExoQuick-TCTM Exosome Isolation Kit for Cell Culture Media 
(System Biosciences, Cat #: EXOTC50A-1) from Promega following manufacturer’s 
instructions. Briefly, 2 ml of ExoQuick-TC was mixed with 10 ml of CM (see above for the 
production of CM), mixed by inverting a few times and incubated overnight at 4 ˚C. Then the 
mixture was centrifuged at 2000xg for 40 min. The supernatant was discarded and the pellet 
was centrifuged for an additional 5 mins to get rid of culture media completely, and the 
resulting pellet was dissolved in DMEM. 
In order to deplete the exosomes from CM, I used an ultracentrifuge. I collected the CM 
freshly, centrifuged to eliminate cell debris and filtered in the same way as explained above, 
and centrifuged the CM overnight at 100,000xg. The pellet was then discarded and the 
exosome-free supernatant was then used for further experiments. 
3.9. Transfection, Virus Production and Transduction 
For overexpressing the QKIs, I used pCMV6-Entry Vectors from BioCat (see below for a 
detailed map of the vector) and transfected the GBMs. Briefly: 0,5 µg of plasmid, pCMV-6, was 
diluted in a total volume of 25 µl of Opti-MEM Reduced Serum Media (Thermofischer 
Scientific, Cat #: 31985062). 1 µl of OMNIfect Transfection reagent (transOMIC, Cat #: OTR 
1001) was also diluted Opti-MEM reduced serum medium and those two mixtures were mixed 
together. The mixture was incubated for 10 mins at room temperature. The mixture was then 
added onto 500 µl of cell suspension, and the cells were incubated at 37 ˚C under 5% CO2/95% 
humidified air for 3 days. pCMV-6 vector contains a neomycin resistance cassette. Therefore, 
the transfected cells were selected via G418 application. The concentration of lethal doses of 
G418 was determined for each GSC line separately, previously. The G418 selection was carried 
out for 2 weeks and cells were then assayed further. 
The knockdown was achieved by shERWOOD-UltramiR-Lentiviral constructs – pZIP-mCMV-
ZsGreen-Puro (see above for a detailed map of the lentiviral vector) through stable 
Figure 1: Method used for chemoresistance assays. 100,000 GSCs were initially plated 
with or without TMZ in either CM or DMEM. The media were exchanged consecutively 
with fresh media with or without TMZ in either DMEM or CM. On day 7, 14 and 21, the 
cells were counted and 100,000 cells were plated back into the same well for day 7 
and 14. On day 21, the final count was performed and the GSCs were discarded. The 
cell number on day 14 and 21 was calculated by assuming that I plated all the cells, 
instead of 100,000. 
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transduction. Using these vectors, I first produced lentiviral particles. I used the TransLenti 
Viral GIPZ Packaging System (from Thermo Scientific, Cat #: TLP4615) for this. I plated 5,5x106 
cells of HEK293T cells in a T75 tissue culture flask in DMEM with 10% FCS, 1% MEM NEAA and 
1% Pen/Strep. I mixed 9 µg of lentiviral vector with 28,5 µg of TransLenti Viral Packaging mix 
in 1 ml of DMEM with no additives, mixed it with 187,5 µl of Arrest-In Transfection reagent 
dissolved in 1 ml of culture medium with no additives and incubated for 20 mins at room 
temperature. Then I aspirated the culture medium from the flask and added 2 ml of the 
transfection mix and completed the medium to 5 ml with addition of plain DMEM. The cells 
were then incubated at 37 ˚C under 5% CO2/95% humidified air for 6 hours. I then aspirated 
the transfection medium and added 10 ml of normal growth medium, DMEM with 10% FCS, 
1% MEM NEAA and 1% Pen/Strep. Incubated again for 3 days and collected the viral particles 
released into the supernatant. The viral titer was not determined and viral suspension was 
frozen at -80 ˚C until further use. 
The transduction was performed similarly for MSCs and GSCs. I counted 100,000 cells and 
diluted in 10 µl of growth medium in a microfuge tube. I added 250 µl of viral suspension 
(thawed on ice prior to use) onto the cells into microfuge tube and incubated them for 1 hour 
at 37 ˚C. After incubation, I took all the mixture and added it into a single well of a 24-well 
plate with 1 ml of appropriate growth medium in total.  For the next 3 days, I exchanged the 
medium with fresh growth medium, and plated the cells in a cell culture flask with a larger 
growth are when required. The knockdown vectors contained a puromycin resistance gene. 
On the 5th day, I started selected cells with appropriate doses of puromycin, determined 
separately for each cell type previously. 
For the lentiviral transductions with a known virus titer (flipped-floxed GFP for GSCs and DsRed 
for MSCs), MOI of 80 was used. 
3.10. RNA Isolation, cDNA Synthesis and Quantitative Real Time PCR 
I isolated the total RNA from 2-5 million cells each time, using RNeasy Mini Kit (Qiagen, Cat #: 
74106), which is based on binding of RNA to a resin and elution via neutralization of binding 
charges on the resin. After isolation of total RNA, the concentration was measured using a 
spectrophotometer and 1 µg was used for cDNA synthesis. 
For cDNA synthesis I used QuantiTect Reverse Transcription kit (Qiagen, Cat #: 205310). This 
protocol involved a DNAse treatment. The cDNA mix was then used for qPCR analysis. 
For the quantitative RT-PCR, I used TaqMan system from Thermo Fischer Scientific. I used the 
quantitative RT-PCR in order to determine the amount of knockdown and overexpression for 
the GSCs and MSCs I manipulated. The device I used was Applied Biosystems StepOne™ Real-
Time PCR System. Negative controls (RNase- and DNase-free H2O) were always included; 
GAPDH was used as positive control and as reference gene; 3 replicates were used for each 
condition (For detailed description, see table below). 
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Quantitative RT-PCR Reaction Mix Component Volume per 20-µl Reaction (in µl) 
20✕ TaqMan® Gene Expression Assay 1 
2✕ TaqMan® Gene Expression Master Mix 10 
cDNA template 2 µg 
RNase- and DNase-free water 7 
Table 1: The components of the RT-PCR reaction mix and volumes for each component per 1 
reaction. The total volume was 20 µl. 
 
The PCR protocol was applied according to the manufacturer’s guidelines. The cycling settings 
are as follows 
50 ˚C 2:00 mins 
95 ˚C 10:00 mins 
95 ˚C 0:15 sec       (40 cycles) 
60 1:00 min 
After the reaction, the fold chance in mRNA abundance for genes of interest were calculated 
using ΔΔCt. 
3.11. Migration Assays 
I cultivated a single spheroid of GBM in a single well of a 96-well plate either in MSC-CM or 
DMEM. Then I captured microscopic images of each spheroid at 0h, 24h, 48h and 72h using 
10X or 5X objectives. I used ImageJ to calculate the area that the cells occupied in each well. 
For this, I determined the scaling of each image using the scale bar I added to each.  I drew a 
line at the borders of the area cells occupied and measured the area within the closed shaped 
line I drew. Then, I divided the measured area by the initial area that the spheroids occupied 
on day 0 (determined right after plating) in order to calculate the fold change in the occupied 
area, and plotted the graphs based on the ratios. 
3.12. Co-culture / Reporter Experiments 
GSCs were transduced with a lentiviral vector (using lentiviral particles with MOI of 80) 
expressing a floxed- and flipped-GFP sequence. I then grew those cells and performed a single-
cell colony assay. Briefly, I dissociated and counted cells, diluted the cells in a way that 1 cell 
will be in 300 µl of growth medium, and plated 100 µl of the mixture in each well of a 96-well 
plate. After the cells grew for 2 weeks, I expanded the cells. Later I divided the cell culture into 
two and assayed one half with the Cre-recombinase. For this, I used tat-Cre recombinase mix 
(Merck Millipore, Cat #: SCR508). I first titrated the tat-Cre recombinase mix for different 
concentrations, as it is toxic to the cells at high concentrations. I used 2 µM of the tat-Cre (Cre 
recombinase fused to tat protein of HIV to ensure the transport of Cre to the nucleus of the 
target cell as tat protein has a nuclear localization signal) mix in 500 µl of cell culture medium, 
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added this mixture onto 50,000 cells (in tubes) and incubated the cells at 37 ˚C for 40 mins. 
Then I washed out the tat-Cre mix with 10 ml of cell culture medium and plated cells into fresh 
cell culture flasks. After 3 days, I checked the cells under fluorescence microscope for the 
existence of GFP positive cells. I picked up the well containing the brightest GFP signal after 
tat-Cre treatment as well as containing no GFP without tat-Cre treatment, for further 
experiments. 
Additionally, I transfected MSCs with a pCDNA-Cre-ERT2-Puro (Kindly gifted by Dr. Jennifer 
Altomonte) expressing a fusion gene of Cre-recombinase and ERT2 estrogen receptor. And 
selected the Cre-positive MSCs with application of puromycin. 
I mixed those GBMs with flipped-floxed GFP with Cre-expressing MSCs at 1:1 ratio. Then I 
plated these cells in 20% FCS medium together and after 24h added 1ug/ml tamoxifen to the 
culture. 72h later, I checked for presence of GFP under a fluorescence microscope. The 
microscope used was Zeiss Axio Vert.A1 Inverted Microscope powered with a Mercury lamp 
and appropriate filters. 
3.13. In Vivo Experiments 
3.13.1. Injected Cells and Mice Models 
I performed two different in vivo experiments. First, I co-inoculated MSCs with mouse GBM 
cells. For this I used a mixture of 10,000 p53KO-PDGFB-GFP cells and 10,000 mouse MSCs 
labeled with DsRed in 1 μl of total volume. These cells were inoculated in C57B/L6 mice brains. 
Later I inoculated TK-expressing GSCs. 25,000 in 1 μl of total volume of GL261-TK-eGFP cells 
were inoculated in C57B/L6 mice. 50,000 in 1 μl of total volume of GBM13-TK-eGFP cells were 
inoculated in Athymic Nude Mice (NU(NCr)-Foxn1nu) 
3.13.2. Anesthesia 
Mice were anesthesized by intraperitoneal injection of 0.1 % xylazyne and 1.5 % ketamine 
hydrochloride mixture in 0.9 % NaCl. The injection was performed as 10 μl of this anesthetic 
mixture per gram of mouse body weight. The eyes of the mice were carefully covered with 
glycerin cream to avoid drying of the cornea. 
3.13.3. Tumor Inoculation 
The tumor implantation was carried out as follows. Anesthetized mice were immobilized and 
mounted on a stereotactic head holder, the top of the skull (bregma) facing upwards. The skin 
of the top of the head was incised and the skull surface was disinfected. 1 mm anterior and 
1,5 mm lateral to the bregma, the skull was pierced with a 20-gauge needle. Then a 1 μl 
microsyringe was inserted till a depth of 4 mm and retracted to 3 mm, to make space and the 
cell suspension was injected into that space. The needle was slowly taken out and the skin was 
sutured. An antibiotic cream was applied on the sutured region. 
3.13.4. Ganciclovir Administration 
In order to treat mice with GCV, 2 strategies were followed. In the first approach, the GCV was 
administered systematically via intraperitoneal injection of a dose of 25 mg/Kg body 
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weight/animal/day. In the other approach, osmotic mini pumps were used. Those pumps were 
loaded with µl 200 of 2 mM GCV solution. After tumor growth of 7 days, both treatment 
regimens were applied for the next 7 days or 14 days. 
3.13.5. Perfusion and Brain Fixation 
For fixation, the mice were anesthesized and perfused with an intracardiac infusion of 0.9% 
NaCl solution, followed by ice cold 4% paraformaldehyde (PFA) solution. Later, the skull was 
broken gently and opened and the brain was postfixed overnight in 4% PFA. Finally, the brains 
were maintained in 30% sucrose solution for cryopreservation. 
The staining for mice brain inoculated with TK-expressing GSCs was performed with 
Hematoxylin and Eosin staining. 
3.14. Data Analysis 
All the data analysis was performed using student’s non-parametric, un-paired t-test. For 
analysis of data, Microsoft Excel was used and for plotting the graphs and performing 
statistical analyses, Graphpad-Prism was used. Significances were depicted as *: p < 0.05, **: 
p < 0.01, ***: p < 0.001, ****: p < 0.0001. Data were presented as mean ± St.dev. 
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4. RESULTS 
4.1. CM from MSCs Modulate the Viability of GBMs in vitro 
CM was produced from bone marrow-isolated MSCs that were cultivated in either with serum 
or serum-free conditions for 72 hours and the viability of an MSC-stimulated GBM cells called 
GBM20 was assessed which are primary GBM cells with stem-like characteristics. The GBM 
viability is negatively affected by the CM from MSCs cultivated under serum-containing 
conditions. Interestingly, the GBM viability was enhanced when they were stimulated with CM 
from MSCs kept under serum-free conditions. These effects were observed with MSC from 
human bone marrow (BM-6, BM-30) or MSC purified from human GBM (gb863; Figure 1). 
 
 
 
 
 
 
 
 
 
4.2. MSCs Home Satellite Tumors in vivo 
I then wanted to investigate, which of these two in vitro conditions is more relevant to the 
pathological situation where MSCs settle in brain tumors in vivo (i.e. if MSCs are in contact 
with blood-serum or they are clustered in areas where blood-serum cannot penetrate). I 
orthotopically inoculated transgenic mouse glioma cells (p53KO-PDGFB-GFP) into the brains 
of immunocompetent mice and 10 days after tumor inoculation, injected genetically labeled 
 
Figure 1: Presence or absence of serum determines the pro- or anti-tumorigenic effects of 
MSCs Left Panel: CM from MSCs (from BM 30, BM6 or gb863 MSCs) that were maintained 
in the presence of serum for 72h was applied on GBM20. After incubation for 72h, the 
viability of GBM20 was drastically reduced. Right Panel: CM from MSCs cultivated in 
serum-free conditions for 72 hours strongly increased the viability of GBM20. (Compared 
to unconditioned medium – 20% FCS and 0 FCS, respectively). The data were analyzed 
using Nalimov test. Controls were arbitrarily set as 1. The differences as compared to 
controls are statistically significant (p < 0.005).  
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MSCs (expressing red-fluorescent protein; RFP). The brains were dissected 20 days after tumor 
induction. As an alternative approach, I co-inoculated mouse glioma cells together with RFP-
expressing MSCs (not shown). In both experimental situations, I observed that, in the main 
tumor mass, there are very few MSCs while in the invasive front of the glioma (satellite tumors 
located distantly from the main tumor mass) the MSC:GBM cell ratio was 1:1 (Figure 2). 
After this observation, I asked the question: why do we see only very few MSCs in the main 
tumor mass despite the relatively high number of MSCs in the satellite tumors? So, I repeated 
the experiment with the same cells in a sequential manner (i.e. MSCs were injected after 
tumor induction). This time I waited only 3 days after MSC injection and dissected the brains. 
Upon this new setting, I was able to observe relatively larger amounts of MSCs in the periphery 
and center of the established gliomas. From this observation I concluded that, MSCs have a 
relatively short life span in the main tumor mass and probably disappear within a few days. 
Yet, MSCs seem to persist for longer periods of time in the satellites, probably, due to absence 
of ever-changing pathological situations and presence of more stable conditions. 
From the above-mentioned in vivo experiments, I concluded that MSC-GBM interaction is 
more stable and relevant in the invasive tumor parts which are buried deep in the tumor 
parenchyma and often located distantly from the main tumor mass. These invasive tumor 
parts are devoid of histopathological hallmarks of glioma, such as hypoxia, inflammation, 
bleedings or necrosis, which, therefore, is a major obstacle in diagnosis and treatment of GBM 
(Jermyn et al., 2016). Given these circumstances, I hypothesized that, MSC-GBM cell 
interaction in invasive tumor front is more relevant and it is best recapitulated in vitro by 
serum-free conditions as blood-derived factors cannot reach such structures that lack 
bleedings. 
The tumor promotion by the CM from MSCs cultivated in serum-free conditions was 
demonstrated previously for GBM20 (Figure 1). Next, I wanted to evaluate how consistent this 
effect of MSCs is observed for different GSCs. Upon stimulation, CM from MSCs cultivated in 
serum-free conditions enhanced the viability of a range of GSCs. The increase in viability varied 
drastically among different GSCs ranging from 1.5X to 10X (Figure 3). Proneural subtype GBMs 
(GBM10; GBM13; Line 7; Line 9) displayed a larger increase in viability than classical and 
mesenchymal subtypes. Due to this heterogeneity in response, GSCs with higher levels of 
viability increase, Line 4, Line 7 and GBM13 were selected for further experiments. 
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Figure 2: MSCs migrate and integrate into the tumor satellites. Mouse glioma cells (p53KO-
PDGFB-GFP) were inoculated together with RFP-expressing MSCs. GBM cells proliferated 
and formed a large tumor mass (Indicated as “Main Tumor Mass”) along with small 
satellites (Indicated as “Satellite Tumor”), shown with Hematoxylin-Eosin stainings in left 
panels of 1st and 3rd row, respectively, where square numbered as 1 shows the main tumor 
mass and square 2 shows satellite. MSC numbers in main tumor mass are significantly low, 
depicted in 1st row – right panel as well as by arrow in the second row where blue color 
indicates nuclear staining, green indicates tumor cells and red shows MSCs. The 2nd row 
shows a close caption of the area indicated in square 1. On the contrary, MSCs are more 
numerous in invading glioma parts than in main tumor mass (shown in “Satellite tumor”, 
square 2). MSC:GBM cell ratio is nearly 1:1. Individual cell populations from a single tumor 
satellite are shown in single channel views, in 2nd and 4th rows for main tumor mass and 
satellite tumor, respectively. Scale bar is 1mm. 
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4.3. MSC-CM Induces the Expression of QKI in GBMs 
My next direction of interest was the molecular signaling mechanism of CM-induced viability 
increase. I analyzed the differentially regulated genes in CM-stimulated GBM13, a GSC that 
responds to MSC-CM by a massive increase in cell number and viability (Figure 3). I exposed 
GBM13 to MSC-CM (serum-free) for 24h, 48h and 72h or DMEM (control medium), harvested 
cells and performed a gene expression analysis via microarray (Figure 4). We used a 
biclustering approach in order to avoid the “noise” caused by large set of genes due to massive 
increase in cell number. Biclustering analysis allows for detection of networks of genes and 
can reveal genetic nodes controlling large physiological pathways [Cheng and Church, 2000]. 
In biclustering method, both genes and samples are compared simultaneously. Comparing 
samples and gene expressions via a biclustering approach in expression matrix, setting 
significance p≥0.05, we diminished the number of target pathways. This way, the clustering of 
genes and samples (also according references in the KEGG-database) converged onto 
pathways which had a specific gene called Quaking (QKI) at the central nodule, shifting further 
away from the controls in a time-dependent manner, showing significance and constant 
increase in expression. Therefore, I concluded that QKI is significantly associated with survival 
and proliferation. 
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Figure 3: MSC-CM (serum-free) increases the viability of GSCs in vitro. GSCs were subjected 
to 72h of stimulation with CM from MSCs cultivated in serum-free conditions. The fold 
change in viability was described as normalized to the control (non-conditioned plain cell-
culture medium) using MTT assays. Data are expressed as fold-change from control levels 
which were arbitrarily set as 1 (indicated with the dashed green line). Statistical 
significance is shown as: *** p < 0.001, ** p < 0.005, * p < 0.05. 
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Figure 4: QKI emerged as a candidate from bioinformatics-analysis of coregulated genes. 
GBMs were treated with CM for 24, 48 and 72 hours. The pellets were collected and 
microarray analysis was performed. Global changes in gene expression patterns are 
graphically indicated. Initially controls (dark-blue) and GBM-cells treated for 24h (green) 
are relatively close, the treated cells shift away from controls after 48h (turquoise) or 72h 
(light-blue) of stimulation with MSC-CM. The more the treated cells are in close proximity 
to the controls on this plot, the less significant the change in expression of a certain gene 
is. The pathways that are activated with an increase in activity in a time dependent manner 
were identified. QKI emerged at the central nodule in these pathways. 
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4.4. Manipulation of QKI in GBMs and EFNA3 in MSCs 
In order to define specific roles of QKI in GBMs in the above-mentioned network, I 
manipulated the expression levels of QKI in different GBM cells by knocking down or 
overexpressing it. QKI has three isoforms, namely QKI-5, QKI-6 and QKI-7. Overexpression was 
achieved by transfection of GBMs (GSCs named Line-4 and Line-7 due to higher proliferation 
rate and easier transfection or transduction than GBM13, which is to be included later on) 
with plasmids encoding separate isoforms (Figure 5, upper graphs). For the knockdown, 
however, I had to use a viral vector encoding an ShRNA which targets the core region shared 
by all three QKI isoforms, simultaneously instead of targeting each isoform separately. With 
these plasmids I was able to overexpress QKI-5 (5-fold in Line 4 and 2,5-fold in Line 7), QKI-6 
(6-fold in Line 4 and 5,9-fold in Line 7), and QKI-7 (4-fold in Line 4, and 3,8-fold in Line 7) (Figure 
5 upper panel). Knockdown of QKIs was achieved up to 98% (Figure 5 lower panel). 
 
4.5. QKI promotes viability of GBM 
After confirming the overexpression of QKI, I performed a viability assay with GSCs Line 4 and 
Line 7 that overexpress QKI isoforms QKI-5, QKI-6 and QKI-7. In these lines, overexpression of 
QKI isoforms lead to an increase in viability compared to those transfected with vehicle control 
(empty) in control medium, DMEM. QKI overexpression even further boosted the viability 
increase by MSC-CM (Figure 6, upper panel). In concordance with this, knockdown of QKIs 
lead to a significant decrease in viability compared to nontargeting vehicle control (NT) in 
DMEM. Knockdown could even blunt the effect of MSC-CM in Line 7 but not in Line 4 (Figure 
6, lower panel). In light of these findings, I concluded that, QKI overexpression is one possible 
explanation for the increase in GBM viability when they are cultivated in MSC-CM. However, 
more cell lines need to be assessed in the same way. Moreover, subjection of QKI knockout 
GBMs to CM from MSCs (serum-free) might shed more light onto this phenomenon. 
Moreover, mass spectrometry of the GBMs stimulated with the MSC-CM might help 
identification of specific molecules. 
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Figure 5: Overexpression and Knockdown of QKI. QKI isomers were overexpressed using 
specific expression vectors for each isomer (Upper Panel). For line 4, this overexpression 
was 4,8-fold for QKI-5; 6,9-fold for QKI-6 and 3,9- fold for QKI-7 (Upper Left Panel). For Line 
7, it was 2,7-fold for QKI-5; 6,1-fold for QKI-6 and 3,8-fold for QKI-7 (Upper Right Panel). 
For Line 4, the knockdown yielded 62% decrease for QKI-5; 90% decrease for QKI-6 and 
98% fo QKI-7 (Lower Left Panel). For Line 7, the decrease for QKI-5 was 60%; 95% for QKI-
6 and 68% for QKI-7 (Lower Right Panel). The relative expression of QKI isoforms in both 
settings are indicated as means normalized to the amount of endogenous GAPDH mRNA 
for each sample ± SD from triplicate data. Normalization was carried out by ΔΔCt method. 
Statistical significance is shown *** p < 0.001, ** p < 0.005 
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Figure 6: QKI-overexpression and -knockdown in GBMs modulate viability and MSC-CM 
induced effects. Upper panel: QKI-overexpression in Line 4 increases the viability in basal 
conditions (DMEM) up to 2,8-fold for QKI-5 and -7 and 4,7-fold for QKI-6 compared to 
vehicle control (Empty). However, this overexpression does not yield a further increase in 
CM, compared to vehicle control that is cultivated in CM, too. For Line 7, QKI-5 
overexpression yielded 2,3-fold increase in viability, whereas, QKI-6 caused a 6,9-fold, and 
QKI-7 caused a 6,4-fold increase in basal conditions (in DMEM). The overexpression of 
QKIs, however, yielded a further increase in viability in CM, compared to vehicle control 
that is also incubated in CM. Lower panel: In line with this, knockdown of QKIs lead to a 
decrease in viability in DMEM, up to 52% for Line 4 and 50% for Line 7. When incubated in 
CM, this knockdown did not cause any decrease for Line 4, however, for Line 7, it 
completely blunted the effect of MSC-CM. Red bars indicate Control Medium (DMEM) and 
Blue bars indicate CM. Statistical significance is shown *** p < 0.001, ** p < 0.005, * p < 
0.05  
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4.6. MSC-CM mediates chemoresistance of GBMs 
So far, I have demonstrated that MSC-GBM interaction mainly takes place in the invasive front 
(i.e. tumor satellites – Figure 2) in vivo. The MSCs migrate to tumor satellites and settle more 
than the main tumor mass. The interaction of MSCs with GBMs leads to an enhanced tumor 
cell viability in vitro although the increase in viability in vitro is heterogeneous among different 
GBM cell lines I used (Figure 3). My aim was to determine if this situation is clinically relevant 
in terms of therapy. During the treatment of a brain tumor with conventional ways, the main 
tumor mass is resected which is followed by a chemo- and radio-therapy. This method of 
treatment, however, cannot eliminate the satellite tumors, which poses a significant risk of 
tumor relapse. As the MSCs improve the GBM cell viability in vitro under serum-free 
conditions, which corresponds to the tumor satellite vicinity lacking blood-borne molecules 
(i.e. MSCs mainly migrate towards satellite tumors), they potentially act in the same way in 
vivo as well. Therefore, there is an eminent need of averting the MSC-mediated tumor cell 
survival. That is why I also asked if MSCs help tumor cells parry the effects of 
chemotherapeutic agent temozolomide (TMZ), which is the conventional chemotherapy drug 
used to treat GBMs. Therefore, I tested the sensitivity of our GSCs to TMZ and observed that 
the extent of sensitivity to TMZ varies among GSCs, monitored by the extent of cell death (data 
not shown). Next, I applied TMZ in combination with MSC-CM onto GBMs that were sensitive 
(Figure 7 – upper panel, Line 4) and slightly resistant (Figure 7 – lower panel, Line 7) to TMZ. 
In this experiment, I applied TMZ as pulses by refreshing the medium containing TMZ every 
24h for 72h and monitored the long-term survival of GSCs in vitro, in order to mimic the clinical 
situation where pulses of TMZ are given to the patients. Additionally, TMZ is an alkylating 
agent whose effects on cell proliferation and survival manifest itself in the long term. 
Consequently, I found out that, MSC-CM largely increases GBM cell numbers (Figure 7) 
compared to relevant controls (i.e. TMZ-treatment in control medium; DMEM; please note 
that changes in cell-numbers are quite large after MSC-CM application, data are given on a 
log-scale). The rescue of GBMs from TMZ-induced cell death by MSC-CM was best visible on 
day 14 of the incubation (Figure 7, bar graphs on the right of both upper and lower panels). 
This is because, after the pulse application of TMZ, GBM cells start to recover, and these cells 
in addition to unaffected or less-effected cell population takes over the cell culture after this 
time point. 
All in all, I demonstrated that MSC-CM massively induces chemoresistance in GBM cells. 
Differences in cells treated with 100 µM or 300 µM TMZ alone or TMZ together with MSC-CM 
accounted to 4 orders of magnitude after 21 days of investigation. The effect of TMZ, however, 
is heterogeneous and the rescue effect of MSC-CM varies among different GBM cell lines. 
Moreover, the GBMs that received TMZ in MSC-CM had comparable cell numbers to those 
received only MSC-CM (control) showing how potent the MSC-CM in negating the effects of 
TMZ in terms of cell death. The rescue effect of MSC-CM from TMZ-induced cell death was 
not only limited to those two GSC lines (Line 4 and Line 7) but also prominent in many more 
of the GSC lines we have (Supplementary Figure 1). 
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Figure 7: MSC-CM renders GSC lines 4 and 7 chemoresistant. I applied TMZ repeatedly for 
72h, with 24h intervals on the first 3 days as pulses by refreshing the medium containing 
TMZ. On days 7, 14, 21, I counted the cells and used 3 replicates for each condition (for 
detailed methodology, see methods – Chemoresistance Assay). The cell numbers were 
determined, then 100,000 cells were plated back. The final numbers on each count (14 
and 21 days) were calculated assuming all the cells were plated back using the equation 
100,000xA = BxC where A=counted cell number (on day 14 or 21), B=total cell number 
from previous count (on day 7 or 14), C=total cell number if all cells were plated (on day 
14 or 21). The total cell numbers (corresponding to B on day 7; C on day 14 and 21) were 
plotted on a semi-log scale (Y-axis as logarithmic scale, X-axis as normal scale – days) for 
scatter-plots and for the bar graphs (demonstrating the largest difference in cell numbers 
which was observed on day 14). Data are presented as Mean ± SD. Statistical significance 
is shown *** p < 0.001, ** p < 0.005, * p < 0.05 
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4.7. MSC-released Soluble Factors largely account for Increased GBM 
Viability and Chemoresistance 
It was shown by others (Baglio et al., 2012) and us that many pathologically important effects 
of MSCs are induced via MSC-released extracellular microvesicles called exosomes. So, I asked 
if the viability increase and chemoresistance are mediated by exosomes or soluble factors. 
To answer this question, I performed two different experiments. First, I depleted exosomes 
from CM as well as isolated exosomes from CM and applied onto GBM13 as the microarray 
data were obtained using GBM13 originally, and GBM13 was one of the GBM lines which gain 
the largest increase in viability upon CM application. Exosomes failed to induce an increase in 
the viability, however, exosome depleted MSC-CM mediated an increase in the viability, at a 
comparable level to that of MSC-CM (Figure 8- a). In the second phase, I applied the TMZ with 
the same settings described above and used either exosome-containing or exosome-free 
media. I observed that both exosome-containing and exosome-free media from MSC-CM 
resulted in significantly more numerous cell counts compared to control DMEM over 21 days 
after TMZ treatment (Figure 8-b). This situation can be explained by the biochemistry of the 
signaling molecules conferring the observed effects. It was previously shown by Roodhart et 
al. that MSCs mediate chemoresistance by releasing bioactive fatty acids (Roodhart et al., 
2011). The bioactive lipid that mediates the increase in cell viability in the presence of TMZ 
treatment accumulates in the lipid phase of the CM along with the exosomes, which is also 
rich in membrane-related lipids. On the other hand, I noted that the exosome fraction is not 
necessary for MSC-CM to confer chemoresistance (exosome-free CM also induces 
chemoresistance of GBMs). In conclusion, a soluble factor (likely a bioactive lipid as MSCs have 
been shown to induce chemoresistance in cancer cells by Roodhart et al. [Roodhart et al., 
2011]) is responsible for the induction of the observed increased viability and 
chemoresistance in GBMs. 
 
 
 
 
 
 
 
 
 
47 
 
D
M
E
M
 C
o
n
t r
o
l
M
S
C
- C
M
E
x
o
s
o
m
e
 
E
x
o
s
o
m
e
 D
e
p
t e
l e
d
 C
M
0
2
4
6
G B M 1 3  E x o s o m e  D e p l e t i o n
R
e
la
t
iv
e
 V
ia
b
il
it
y
* * *
*
n s
* * * *
Line 7 TMZ Response with Depleted CM
0 7 14 21
104
105
106
107
108
109
DMEM Control
DMEM 100 µM TMZ
CM Control
CM 100 µM TMZ
Depleted Control
Depleted 100 µM TMZ
Days
T
o
ta
l 
C
e
ll
 N
u
m
b
e
r
L i n e  7  D e p l e t e d  1 4  D a y s
1 0
0
1 0
1
1 0
2
1 0
3
1 0
4
1 0
5
1 0
6
1 0
7
1 0
8
1 0
9
D M E M  C o n t r o l
D M E M  1 0 0  µ M  T M Z
C M  1 0 0  µ M  T M Z
D e p l e t e d  C o n t r o l
C M  C o n t r o l
D e p le t e d  1 0 0  µ M  T M Z
C
e
l
l
 
n
u
m
b
e
r
* * *
* *
* *
* * *
* *
n s
n s
n s
A 
B 
48 
 
Line 4 TMZ Response with Depleted CM and Exosome
0 7 14 21
1.01002
1.01003
1.01004
1.01005
1.01006
1.01007
1.01008
1.01009
DMEM Control
DMEM 100 µM TMZ
CM Control
CM 100 µM TMZ
Depleted Control
Depleted 100 µM TMZ
Exosome
Exosome 100 µM TMZ
Days
T
o
ta
l 
C
e
ll 
N
u
m
b
e
r
L i n e  4  -  E x o s o m e  a n d  D e p l e t e d  1 4  D a y s
1 0
0
1 0
1
1 0
2
1 0
3
1 0
4
1 0
5
1 0
6
1 0
7
1 0
8
1 0
9
1 0
1 0
D M E M  C o n t r o l
D M E M  1 0 0  µ M  T M Z
C M  1 0 0  µ M  T M Z
D e p l e t e d  C o n t r o l
C M  C o n t r o l
D e p le t e d  1 0 0  µ M  T M Z
E x o s o m e
E x o s o m e  1 0 0  µ M  T M Z
C
e
ll
 n
u
m
b
e
r
* *
* * *
* * *
* * *
* * *
n s
n s
n s
* * *
n s
* * *
 
 
Figure 8:  MSC-released soluble factors confer viability and chemoresistance. A. Exosomes 
were depleted by ultracentrifugation or isolated from MSC-CM. They were then applied 
onto a GSC line, GBM13. The exosomes failed to boost the viability of GBM13, however, 
exosome depleted MSC-CM induced an increase in viability, at a comparable level to that 
of MSC-CM alone. B. GSCs were challenged with TMZ in the presence of conditioned media 
from MSCs (CM), purified exosomes, exosome-free CM (depleted) or with non-
conditioned media (DMEM).  Exosome-depleted medium was fully capable of mediating 
TMZ resistance in GBM cells (Depleted) The observed cell numbers were comparable to 
those of GSCs subjected to TMZ in the presence of CM. The cell counts when GSCs were 
maintained with exosomes were not statistically different from controls, showing that 
exosomes do not confer a chemoresistance, as shown for Line 4 (Lower Panels). The rescue 
effects of CM and Depleted media were most pronounced on day 14 after TMZ treatment 
(Left Panels, Scatter Plots. GBM Cells start to recover after that time point – See 
Chemoresistance Assay), and cell numbers on day 14 were shown by bar graphs (Right 
Panels on a log-scale). Data are indicated as Mean ± SD. Statistical significance is shown 
*** p < 0.001, ** p < 0.005, * p < 0.05  
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Quaking-6 (QKI-6) Mediates the MSC-CM-induced Increase in Viability and 
Chemoresistance 
Previously I have shown that the QKI expression is induced in GBMs by MSC-released soluble 
factors and that QKI expression is necessary for GBMs to gain an increased viability (Figure 6). 
Therefore, my next question was if increased QKI expression alone is capable of inducing the 
above-mentioned chemoresistance in GBMs. In order to investigate that scientific question, I 
utilized the GSCs overexpressing QKI (three different isoforms named QKI-5, QKI-6 and QKI-7) 
and treated them with TMZ. I demonstrated that QKI expression (for all three isoforms) alone 
was able to confer chemoresistance in GSCs. However, the rescue was most pronounced for 
QKI-6, whereas QKI-5 and QKI-7 caused a modest rescue Line 4 from the effects of TMZ (Figure 
9). 
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Figure 9: Overexpression of QKIs, is sufficient to induce TMZ-resistance in GBM. GSC line 4 
either overexpressed different QKI-isoforms (QKI-5; QKI-6 and QKI-7) or contained an empty 
control vector (red bar). GSCs with empty vector were sensitive to TMZ treatment and acquired 
chemoresistance by MSC-CM.  Overexpression of QKI (most strongly QKI-6 isoform depicted by 
yellow bars) was sufficient to induce chemoresistance in GSCs. Differences between the DMEM 
and DMEM-QKI-6 samples are statistically significant (p < 0.005). Data were presented as Mean 
± SD.  
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4.8. QKI de-repress EGFR 
I showed earlier that, a soluble factor (likely a bioactive lipid) is required to induce changes in 
the gene expression pattern in GSCs stimulated by the MSC-CM, where QKIs play an important 
role. Moreover, MSCs induce the chemoresistance in GBMs in vitro and QKIs are one 
important factor in this interplay. Additionally, knockdown of QKI expression levels caused a 
significant reduction in the viability of GBMs under control conditions and negated the 
induction of viability increase in the presence of MSC-CM stimulation (Figure 6 – Lower 
Panels). That is why it was important to know how QKIs have such drastic influences on GBM 
cell viability. Additionally, QKI is an intracellular signaling factor, which proves to be 
inaccessible for targeting for therapeutic purposes. With these in mind I investigated the 
molecular stakeholders of this signaling network and found out that, reductions in QKI levels 
by knockdown causes a decrease in the expression levels of EGFR (Figure 10). It was shown by 
others (Wang et al., 2013) that QKI, being a member of STAR – RNA binding protein family, 
can sequester MiRNA-7 in nucleus in the form of pri-MiRNA while being processed. MiRNA-7 
targets EGFR and the abundance of QKIs increase the sequestering, thereby increasing the 
abundance of EGFR, which promotes cell division and survivability. Currently open question is 
if EGFR blockers can have beneficial effects in terms of GBM treatment, also in combination 
with TMZ. 
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Figure 10: QKI-knockdown results in a decrease in EGFR levels in Line 4. Quantitative real-
time PCR analysis of total RNA from Line 4, with QKI knockdown, using TaqMan probes 
directed to EGFR displayed a decrease in EGFR levels in the QKI-knockdown cells (Q-13), 
compared to controls (NT). The difference between control and the knockdown bar is 
statistically significant (*** p < 0.001). This shows that QKI knockdown causes a decrease 
in EGFR levels.  
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4.9. MSC-derived Exosomes Promote GBM-invasion via EFNA3 Induction 
Previously I demonstrated that the interaction between GBMs and MSCs mainly takes place 
in the invasive areas of the tumor i.e. tumor satellites (Figure 2). Here, MSCs might be 
supporting the viability of GBMs while they are invading the brain, which in turn lead to a 
tumor relapse in the long term. GSC cultures grow as spheroids under control conditions in 
vitro. However, during my experiments where I measured the viability of GBMs upon serum-
free MSC-CM and exosome stimulation, I noticed that MSC-CM causes an adherence followed 
by a morphological change in the recipient GBMs. In order to test this further, I cultivated 
GBMs in serum-free MSC-CM or in the presence of MSC-released exosomes dissolved in 
control medium. I observed that GBM cells undergo drastic morphological changes when 
incubated in MSC-CM and in exosome-medium, reminiscent of motile cells, which was not 
observed in exosome-free and control medium (Figure 11). However, those morphological 
changes were not observed in all GSC lines, but mostly limited to proneural and mesenchymal 
subtypes of GSCs. Therefore, I chose the GSC lines with relatively high levels of morphological 
changes for further experiments regarding exosomes. 
 
 
 
 
 
 
 
 
 
 
 
My next aim was to explore if exosomes contain molecular factors that induce the migratory 
behavior observed in GBMs which eventually contribute to increased GBM invasion. In the 
biclustering analysis for co-regulated pathways, there were no genes with an apparent 
potential to mediate cell motility. However, MSCs exert their effects not only via soluble 
factors but also via exosomes which carry signaling molecules with pronounced pathological 
Figure 11: MSC-CM as well as MSC-derived exosomes induce profound morphological 
changes in GSC. GSC cultures grow as spheroids under control-conditions (Control panel 
shows representative phase contrast image of GBM cells maintained under stem-like 
conditions in vitro); upon exposure to MSC-CM from MSCs grown in serum-free conditions 
(MSC-CM) GSC spheroid cultures undergo large morphological changes within 48h, i.e. 
spheroid attached and single cells migrating away from the spheroids. However, the 
morphological changes induced by MSC-CM were not visible when exosomes were 
depleted from MSC-CM by ultracentrifugation (Exosome-free MSC-CM). When GSCs are 
maintained in MVs purified from MSC-CM from serum-free conditions, they undergo 
pronounced morphological changes (Exosome from MSC-CM). 
Control MSC-CM Exosome-free MSC-CM Exosome from MSC-CM 
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implications (Baglio et al., 2012). Those signaling molecules include mRNAs that can be 
translated by the recipient cells which eventually lead to cellular changes. However, although 
the amount of such intravesicular mRNAs is extremely low, much lower than those produced 
in a cell, they trigger vast variety of pathological outcomes [Hood et al., 2011; Zhang et al., 
2011; Roodhart et al., 2011]. So, I needed a new way of investigating such small quantities of 
genetic materials in exosomes and the transfer from MSCs to GBMs via exosomes. Therefore, 
I obtained expression profiles, by RNASeq, from GBM cells stimulated with exosomes, GBM 
cells under control conditions, and the exosomes derived from MSCs (Figure 12). 
Such analyses of genome-wide multiple comparisons often generate large sets of differentially 
expressed genes which might prove rather complicated to handle. However, some relevant 
genes can be identified in such bundles of data by comparing multiple samples in line of the 
question in hand. Therefore, I compared differentially expressed genes in exosome-treated 
GBM13 and control GBM13, using a cutoff value of 1,5-fold change in expression and 
narrowed down the number of genes to a manageable size. Moreover, I anticipated that the 
factor responsible for such morphological changes should be an mRNA with an annotated 
function which is carried within exosomes as most of the sequences emerged from these 
statistical analyses were epigenetic modulators corresponding to largely unknown pathways 
(Figure 13). 
Consequently, I was able to narrow down my search of pathologically relevant genes greatly 
by combining these data from microarray data where I identified QKI as a target for increase 
in viability and RNASeq data from MV-stimulated GBM13 (Figure 4, Figure 12 and Figure 13). 
As a potential target responsible for those effects, I designated ephrin ligand 3 (EFNA3). 
Because, EFNA3 levels were very low in the control GBMs, but enriched up to 1,9-fold in 
exosome-stimulated GBMs and numerous in exosome cargo with 7-fold, compared to 
controls. 
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Figure 12: Gene expression profiling by RNASeq identified mRNAs in MSC-MVs which 
contribute to modulation of gene expression changes in recipient GBM cells. GBM13 cells 
were maintained under control conditions (Control) or treated with MSC-derived 
exosomes (STIM). Those cell fractions as well as exosomes alone were then analyzed by 
RNASeq. All samples were compared with each other Left Panel – Control vs Exosomes; 
Middle Panel – Control vs MV-Stimulated GBMs; Right Panel – Exosomes vs MV-Stimulated 
GBMs) and the identity of differentially expressed genes (one dot represents one gene) as 
well as fold-changes in gene expression (plotted on the x-axis) were obtained. Significant 
changes were statistically tested (y-axis) and altered gene expression levels for each 
identified gene (blue dots) were retrieved. Stimulation of GBM cells with MV produced 
only a relatively small number of altered genes (central figure). 
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Figure 13: The pie-chart for RNA reads and respective annotations from exosomes alone. 
The RNAs analyzed in the exosomes were classified based on functions. mRNAs (RefSeq 
exons) were low in numbers but tRNAs dominate the overall reads. Additionally, 
epigenetic modulators corresponding to largely unknown pathways were found in 
exosomes.  
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4.10. EFNA3 Mediates the Morphological Change / Adherence of GBMs 
Previously, RNASeq screen proved EFNA3 to be a relevant target. Hence, I manipulated the 
EFNA3 in MSCs, which is its source. I was able to reduce the expression levels of EFNA3 in 
MSCs up to 50% (Figure 14). 
 
 
I subjected GBMs to MSC-CM derived from MSCs that are either EFNA3 knockdown (E3) or 
transduced with non-targeting ShRNA control vector (NT). Then I quantified the adherent 
GBM percentage for different GBM lines, keeping in mind that the adherence was the first 
indication of above-mentioned morphological changes. GBMs cultivated in CM from MSCs 
with EFNA3 knockdown (E3) displayed significantly reduced adherence compared to those 
cultivated in CM from control MSCs (NT), shown for GSC lines GBM13, Line 6, Line 9 and Line 
11 (Figure 14b). Expectedly, different GSC lines differ in their percentage of adherence, most 
probably attributable to their different subtypes and genetic backgrounds. 
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Figure 14: EFNA3 knockdown in MSCs. The 
knockdown was achieved by a decrease of  
52% with E3 construct (among 2 others – 
not shown). statistical significance is 
shown *** p < 0.001 
56 
 
 
 
 
 
 
 
 
 
4.11. EFNA3 promotes the Migration of GBMs 
In the previous section I demonstrated that the percentage of adherent GBM cells was 
decreased upon cultivation in CM from MSCs with EFNA3 knockdown. Additionally, I reasoned 
that those morphological changes starting with adherence are reminiscent of cell migration 
and adherence is the pre-requisition of migration in vitro. Therefore, now I investigated if 
EFNA3 knockdown in MSCs cause a decrease in the migration of GBMs. For this purpose, I 
developed a migration assay where I plated a single spheroid in each well of a 96-well plate 
and quantified the occupied area of GBMs over 3 days normalizing it to the initial spheroid 
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Figure 15: EFNA3 knockdown in MSCs decreases the adherence of GBMs upon CM 
exposure.  The GBMs were exposed to CMs from MSCs with EFNA3 knockdown (E3-CM) 
or CM from control MSCs (NT-CM). GBMs stimulated with E3-CM displayed a 
significantly reduced adherence compared to control, NT-CM. This decrease was 25% 
for GBM13, 20% for Line 6, 20% for Line 9 and 17% for Line 11 compared to vehicle 
control (NT). It is noteworthy that these GBM lines have different adherence levels at 
basal conditions (in DMEM). statistical significance is shown *** p < 0.001, ** p < 0.005, 
* p < 0.05 
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area to be able to precisely detect the changes in migrated area each day (See methods for a 
detailed methodology). I cultivated spheroids in either CM from MSCs with EFNA3 knockdown 
(E3-CM) or control MSCs (NT-CM). I found out that, EFNA3 knockdown in MSCs significantly 
reduced the occupied area which is an indication of the migration, and thereby the invasive 
behavior of GBMs compared to control, NT and DMEM (Figure 15). The migrated area, 
however, varies among different GSC lines, so is the reduction in migrated area due to EFNA3 
knockdown in MSCs. 
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Figure 16: EFNA3 knockdown in MCSs 
results in a decrease in the migration of 
GBMs. Occupied surface area of GSCs 
(GBM13, Line-8 and Line-9) was arbitrarily 
set as 1 for control medium (DMEM). 
GSCs were then stimulated with either 
CM from MSCs with EFNA3 knockdown 
(E3) or with control MSCs containing a 
non-targeting vector (NT). EFNA3 
knockdown lead to a pronounced 
decrease in migrated area at 72h. The 
reduction was 40% for GBM13, 30% for 
Line-8 and 32% for Line-9, compared to 
NT. Statistical significance is shown *** p 
< 0.001, ** p < 0.005, * p < 0.05 
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In line with this, I next questioned if overexpression of EFNA3 induces an increased migration 
in GSCs. Therefore, I overexpressed EFNA3 in MSCs up to 7.2 fold (Figure 17) 
Next, I cultivated the same GSCs as above (GBM13, Line-8 and Line-9) in CM from EFNA3-
overexpressing MSCs (mEFNA3-OE) and control MSC (Empty). I observed that, EFNA3 
overexpression lead to a moderate increase in the migrated area for GBM13 alone, but not 
for Line-8 and Line-9 (Figure 18) which could be attributed to a saturation of migratory 
behavior at the basal level of EFNA3 expression, in the latter. 
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Figure 17: EFNA3 overexpression in MSCs. In order to overexpress EFNA in MSCs, I 
transfected them with an overexpression vector encoding EFNA3 sequence (see 
methods for more detailed information about the vector used) and overexpression 
was assessed by quantitative real time PCR using TaqMan probes which demonstrated 
an increase of 7.2-fold in EFNA3 expression. Data were indicated as Mean ± SD. 
Statistical significance is shown *** p < 0.001 
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Figure 18: EFNA3 overexpression in MCSs results in a moderate increase in GBM13 but not 
in other GSCs. Occupied surface area of GSCs (GBM13, Line-8 and Line-9) was arbitrarily 
set as 1 for control medium (DMEM). GSCs were then stimulated with either CM from MSCs 
with EFNA3 overexpression (mEFNA3 OE) or with control MSCs containing an empty vector 
(Empty CM). EFNA3 overexpression lead to a moderate increase in migrated area for 
GBM13 alone, at 72h, compared to control NT. The increase was 42% for GBM13. Statistical 
significance is shown *** p < 0.001, ** p < 0.005, * p < 0.05 
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As an alternative approach for proving the role of EFNA3 in migration, I overexpressed EFNA3 
in HEK293 cells, which have no apparent expression of EFNA3 and release vast amounts of 
exosomes. I produced serum-free CM from EFNA3-overexpressing HEK293 (EFNA3-OE) cells 
or those carrying an empty vector (Empty) and applied on GSCs. CM from EFNA3 
overexpressing HEK293 cells induced a significantly increased migration of GSCs, compared to 
control DMEM and Empty-CM (Figure 19). 
In the previous sections, I demonstrated that EFNA3 mRNA is carried from MSCs to GBMs 
within exosomes. In turn, EFNA3 mRNA induces the migration via an unclear mechanism. 
Knocking down the EFNA3 in MSCs resulted in a marked decrease of the migration of GBMs 
upon exposure to CM (serum-free). In order to strengthen this finding with additional proves, 
I expressed the knockdown ShRNA in GSCs to eliminate the endogenous EFNA3 as well as the 
EFNA3 mRNA delivered by the exosomes from MSCs. Moreover, I stimulated EFNA3 
knockdown GSCs with either CM or exosomes purified from MSCs. Elimination of exosome-
delivered EFNA3 in GSCs (#9-E3) lead to a pronounced decrease of the occupied area 
compared to control (#9-NT) when stimulated with exosomes. Moreover, the EFNA3 
knockdown completely abrogated the effect of CM stimulation in terms of migration (Figure 
20). 
 
 
Figure 19: GSC migration is induced when EFNA3 is overexpressed in HEK293 Cells. HEK293 
cells have no detectable expression of EFNA3. CM from HEK293 cells overexpressing EFNA3 
or containing an empty vector was produced in serum-free conditions and GSC migration 
was measured over the course of 72h. CM from HEK293-EFNA3-overexpression dramatically 
induced migration of GSCs (Line-8) while CM from HEK293-Empty did not induce any 
migration. Data were presented as Mean ± SD. Statistical significance was shown; **** 
p<0,0001 
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4.12. Message Transfer via Exosomes from MSCs to GBMs 
In the previous sections, I demonstrated that, EFNA3 mRNA is transferred from MSCs to GBMs 
via exosomes. Now I wanted to prove the concept that, MSCs package functional mRNAs into 
exosomes and this “message” is translated and activated in GBMs. Moreover, we do not know 
how frequently this transfer of mRNA via exosomes takes place in vivo. Additionally, it is 
pivotal to track individual cells receiving exosomes from MSCs in terms of metastatic 
infiltration to uncover specific role of the transfer of mRNAs. Therefore, I generated a reporter 
system by expressing Cre-recombinase in MSCs and a floxed-flipped-GFP in GBM13 in order 
to permanently label the GBMs which had taken up exosomes from MSCs (Figure 11 – upper 
panel). It was previously shown that Cre-recombinase is packaged in exosomes, taken up by 
target cells (In our case GBMs) and expressed into functional protein product and activates 
the expression of flipped-GFP (Ridder et al, 2012). To test the functionality of the system, I co-
cultured this transgenic MSCs and GBM13 cells. After 72h, I was able to detect GFP-positive 
GBMs in co-culture conditions but not in control (GBM13 alone), which is an indication of Cre-
mRNA transfer from MSCs to GBMs (Figure21– lower panel). However, this observation was 
not very frequent, so we do not know if this system could be used in vivo at this stage. 
Improvements are needed before in vivo studies. 
Figure 20: Knockdown of EFNA3 in GSCs have profound effects on migration. EFNA3 
knockdown construct (E3) was expressed in GSCs to knockdown of endogenous EFNA3 
mRNA and decrease the effects of exosome-delivered EFNA3. GSCs were stimulated both 
with CM (left graph) and exosomes purified from MSCs (right graph). Knockdown of both 
endogenous and exosome-delivered EFNA3 (#9-E3) caused a marked decrease of the 
occupied area, hence migration, of GSCs when stimulated with exosomes compared to 
control (#9-NT), but completely blunted the effect of CM stimulation (left graph - #9-E3 in 
CM). Data were presented as Mean ± SD. Statistical significance is shown *** p<0,001; 
**** p<0,0001. 
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4.13. Tumor Satellite Model 
From the initial in vivo experiments, I concluded that the MSC-GBM interaction takes place at 
the tumor satellites, instead of the main tumor mass. Later, the in vitro experiments mimicking 
the conditions that are present at the tumor satellites demonstrated that the MSCs have pro-
tumorigenic effects on GBMs such as increased viability and chemoresistance (mediated by 
QKI) and invasion (mediated by EFNA3 transferred by exosomes) which overall augment GBM 
relapse. Therefore, it is pivotal to study those interactions in vivo. In order to test this 
hypothesis, we would need a relevant in vivo model where we could recapitulate the standard 
series of treatment. However, it is very difficult to perform tumor resection in a mouse brain 
due to its small size and alternative glioma models for studying tumor relapse are not wide-
spread. That’s why I tried to establish such a model which allows for reproducible mimicking 
of tumor debulking. In GBMs, I overexpressed thymidine kinase (TK), which functions as a 
suicide gene upon application of the prodrug Ganciclovir (GCV) by converting it into a cytotoxic 
residue inducing cell death. For this, I used TK-expression vector, normally used for gene-
Figure 21: mRNA exchange between MSCs and GBMs in vitro. MSCs were stably 
transfected with Cre-recombinase expression vector, and GBMs were stably transduced 
for expression of an inactivated flipped form of GFP. Then those two were cultivated 
together. This resulted in “turning on” of the GFP expression in GBMs. This proves the 
transfer of Cre-mRNA from MSCs to GBMs. Three white rectangles show independent 
areas where GBMs have taken up exosomes carrying Cre-mRNA (depicted as 1,2,3). GBM 
cells with activated GFP expression upon taking up exosomes from MSCs expressing Cre-
recombinase are indicated with arrows. Scale bars are 50 um. 
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therapy purposes (by Hrvoje Miletic, University of Bergen, Norway). These GBM cells 
expressing TK were inoculated in mice and after tumor growth of 7 days, intracerebral osmotic 
minipumps loaded with 2 mM GCV were implanted. This experimental model allowed for 95% 
reduction of tumor size on day 21 (Figure 22). 
As an alternative approach, I sought to infuse GCV intravenously, instead of using osmotic 
minipumps. The advantage is that, this method is broadly applied without any advanced 
surgical skills, does not add another experimental parameter (the effects of osmotic pumps 
are required to be controlled) and can be combined with other therapeutic treatments easily. 
Therefore, I recapitulated the above-explained experiment with several experimental groups 
of mice including relevant controls for proper glioma growth without GCV treatment, for 
GBMs without TK expression in the presence of GCV along with experimental situation where 
GBM cells expressed TK and GCV was injected to reduce the size of the tumor mass. 
Intravenous injection of 25 mg/Kg body weight/animal/day GCV resulted in a similarly reduced 
tumor mass (Figure 23) 
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Figure 22: GBM13 cells (of human origin) expressing TK were implanted into 
immunocompromised mice. After 7 days of tumor growth, 2 mM GCV was infused via 
osmotic minipumps for 7 days (left panel) and for 14 days (right panel). GCV treatment 
massively reduced the size of the main tumor mass, which was not observed in the 
negative controls such as TK-free GBMs with GCV infusion and TK-expressing GBM 
receiving saline infusion (not shown).  
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Figure 23: GBM cells (the human GSC GBM13) expressing TK were implanted into 
immune-compromised mice. Tumor growth was allowed and different concentrations of 
GCV were applied to different experimental groups of mice. Data are presented from one 
experimental cohort receiving 25 mg GCV / kg body-weight / animal / day. Experiments 
were performed with n = 4 mice per time point (16 mice per experimental group + 4 
additional controls) and in a total of 3 different cohorts receiving different amounts of 
GCV (60 mice in this experiment). (A) GBM-13 cells expression TK formed 
histopathologically detectable gliomas within 21 days in absence of GCV. (B) Short-term 
GCV treatment (starting 7 days after glioma inoculation and ending 14 days after glioma 
injection) indicated a reduction in tumor mass. (C) Gliomas were massively shrunk after 
14 days of GCV application.  
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4.14. SUMMARY 
GBMs have proven to be a major pathology with vast infiltration potential and extreme 
chemo- and radio-resistance leading to devastating outcomes. The GBMs, however, are not 
only detrimental on the host alone but also they interact with the microenvironment to 
manifest some of their pathological hallmarks. Within the tumor microenvironment, MSCs 
have gained a strong attention in the recent years. The role of MSCs within the brain tumor 
niche has been partially explained including pro- and anti-tumorigenic effects. It was, 
however, a controversial issue as to what makes MSCs pro- or anti-tumorigenic. Moreover, 
the contribution of MSCs in the brain tumor histopathology was not yet fully uncovered. 
Here I investigated the role of MSCs in the brain tumor pathology and the signaling 
mechanisms. It was shown earlier in our lab that MSCs act as anti-tumorigenic in the presence 
of serum and anti-tumorigenic in serum-free conditions. Which condition is more relevant to 
the pathological situation was an open question. When I co-inoculated MSCs with GBMs, they 
homed the tumor satellites, where they are probably not in contact with blood-borne factors. 
Therefore, I concluded that serum-free conditions are more relevant to in vivo pathological 
situation. 
MSCs promoted viability of many primary GSC lines under serum-free conditions. The 
induction of survival and proliferation was mediated by the increase in the levels of QKIs in 
GBMs upon exposure to MSC-derived soluble factors. In turn, QKIs increase the levels of EGFR 
causing an overresponse to growth factors. Moreover, increased QKI-levels in GBMs mediate 
the chemoresistance against TMZ. In addition to soluble factors, MSCs signal via exosomes. 
Those exosomes carry EFNA3 mRNA from MSCs to GBMs. EFNA3 expression in turn induces 
cellular migration. The inhibition of EFNA3 transfer via genetically engineered antibodies 
against exosome docking sites on the recipient GBM cells or against EFNA3 (if it is translated 
and integrated on the surface) as well as EGFR-blockade might prove useful for future 
therapeutic approaches against GBMs. 
There are no well-established mouse models to study the interaction between MSCs and 
GBMs at the tumor satellite. Therefore, I sought to establish such a model by expressing HSV-
TK in GBMs and inducing cell death via GCV administration either by osmotic pumps or via 
systemic injection and established a model where one can study tumor satellites. Additionally, 
I established a model to study the mRNA transfer from MSCs to GBMs. For this, I expressed 
Cre-recombinase in MSCs, and flipped- and floxed-GFP in GBMs. The Cre-recombinase mRNA 
is packed into exosomes and delivered to GBMs, labelling GBMs with GFP for the rest of their 
lives. This enables us to demonstrate the transfer of mRNA as well as to track individual GBM 
cells, contacted by the MSCs, in terms of their migratory behaviors in vivo. All in all, I 
uncovered a previously unknown action of MSCs in GBM pathology defining two targetable 
systems (EGFR and EFNA3) and established two models to study in vivo interaction of MSCs 
with GBMs. 
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5. DISCUSSION 
5.1. MSCs Continuously Home Tumors 
MSCs have the ability to locate and integrate within the tumor tissue, which is termed as 
“homing”. This homing behavior is guided via some tumor-specific receptors and soluble 
tumor-derived factors like SDF-1, TNF-α, and interleukins. Once they reach the tumor, they 
perform either pro- or anti-tumorigenic roles which include, but not limited to, immune 
response suppression [Djouad et al, 2003], inhibition of apoptosis in tumors [Ramasamy et al, 
2007], stimulation of epithelial to mesenchymal transition (EMT) [Martin et al, 2010], tumor 
cell proliferation [Liu et al, 2011], angiogenesis [Hung et al, 2005], tumor cell migration 
[Corcoran et al, 2008], invasion [Corcoran et al, 2008] and metastasis [Karnoub et al, 2007]. 
GBMs exhibit a hard vascularization containing incomplete circulation with open-end blood 
vessels, causing leakage similar to all tumors. In this respect, tumors are termed as wounds 
that do not heal. MSCs are thought to reach brain tumors via those blood vessels. As the 
tumors are called wounds that do not heal, MSCs act as if they are healing wounds. MSCs have 
two phases of injury response called early and late response. In early injury response MSCs 
induce pro-inflammatory pathways in the injury site to promote clearance of the wound from 
infectious agents. In the late injury response, MSCs induce local stem cells for scar formation, 
tissue repair and eventually wound healing. Early response could be relevant to the anti-
tumorigenic roles of MSCs. Tumors have the ability to suppress immune cells and corrupt them 
for their benefits. By elevating immune response, MSCs increase the tumor cell clearance by 
the immune system. Late response might explain the pro-tumorigenic effects of MSCs. They 
secrete factors that stimulate local stem cells to proliferate for wound healing, which triggers 
cancer stem cells to proliferate as well. 
Furthermore, by different research groups, MSCs have been shown to differentiate into 
different stromal cell types and support the tumor in a variety of ways, such as differentiating 
into Cancer-associated fibroblasts (CAFS) in peripheral tumors [Gao et al, 2009]. Djouad et al, 
in 2003, also demonstrated that MSCs do not require an integration into the tumor stroma in 
order to perform the afore mentioned roles but they are able to stimulate similar outcomes 
in terms of tumor pathology with paracrine signaling [Djouad et al, 2003]. Roodhart et al in 
2011 also showed that MSCs can also mediate and support chemoresistance in tumors where 
they made a modelling experiment mimicking the mobilization and integration of MSCs into 
tumor stroma [Roodhart et al, 2011]. 
In this study, I tested the potential of MSCs locating GBM xenografts in vivo. I inoculated MSCs 
following GBM inoculation and tumor formation. The MSCs were inoculated at a distance of 
1.5 µm from GBM tumor mass. Only very few MSCs were observed in the main tumor mass, 
whereas ratio of MSCs to GBM cells in the satellite tumor was close to 1:1. This finding is 
consistent with the observations made by others where MSCs were more successful at homing 
satellites than the main tumor mass [Bexell et al., 2009]. This phenomenon could be 
therapeutically important because main tumor mass is surgically removed with ease while 
satellites are mostly out of reach and cannot be easily detected with conventional noninvasive 
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methods until they grow up to a certain size [Tilghman et al., 2014]. Using MSCs as tools, or 
targeting their interactions with GBM satellites may prove a useful means of therapy 
development. However, mouse brain is too small for noninvasive surgical operations and not 
many alternative tumor models exist for studying satellite tumors. To address this problem 
and explore the MSC-GBM satellite interaction in vivo further and to develop potential 
therapeutic approaches, I developed a tumor satellite model where I used a suicide gene in 
GBM cells which can be triggered with GCV infusion, eliminating a majority of GBM cells 
leaving behind small clusters of cells that develop into satellite tumors later. In the early 
experiments where I tested this system, I could achieve satellite tumor formation upon GCV 
infusion via osmotic pumps, or intraperitoneal injection. The size of the tumor was dependent 
on the duration of the GCV application, i.e. more prolonged application of GCV lead to smaller 
tumor sizes, 14 days being the ideal time for a satellite-size tumor to form. This system can be 
improved with later studies to test the precision and relevance to the pathogenesis of the 
GBMs in patients. 
5.2. MSCs Have Profound Effects on GBMs 
We demonstrated that, MSCs cultivated in the presence of FCS have different physiological 
effects on GBMs than those maintained in FCS-free medium. This difference was evident in 
the GBMs treated with MSC-CM from both MSC-cultivation conditions. This finding supports 
the finding that MSC secretome varies based on the conditions they reside in [Vizoso et al., 
2017]. When MSCs integrate into the tumor stroma in satellites, they are no longer in contact 
with the blood stream unlike they used to be in the bone marrow (and in main tumor mass 
which exhibit a large angiogenesis [Brat et al., 2003]) as satellite tumors do not possess a hard 
vascularization. This means, they are no more able to receive stimulation from blood borne 
stimulants such as chemokines and growth factors. In order to mimic the exact same situation, 
we cultivated our MSCs in the absence of FCS which contains the similar or the same 
stimulants of blood stream. 
5.3. MSC-CM Effect is Different for Different Cell Lines 
When MSCs were cultivated in serum-free medium and this CM was applied onto GBMs, the 
viability of GBMs was significantly increased. The extent of this increase in viability of GBMs 
varied greatly among different lines. Moreover, some cell lines didn’t even respond to CM in 
terms of increase in the viability. This could be due to cell-intrinsic properties which varies 
from cell to cell. The GBMs have been attributed to three different subtypes which are defined 
by the gene expression patterns [Verhaak et al., 2009]. In addition to these different gene 
expression patterns, the GBM lines I used were primary GBMs derived from patients, 
therefore they possessed different genetic backgrounds, too. In the normal growth medium, 
they displayed different growth patterns as well as different morphological properties. Given 
these genetic and physiological variations, the CM from MSCs might have different potencies 
for each cell line. Proneural GBMs have been shown respond CM with the highest increase in 
the viability, whereas mesenchymal GBMs displaying the lowest response in terms of increase 
in viability. Additionally, even each cell line that belongs to the same subtype has differences 
in terms of the degree of increase in viability, demonstrating the complexity of the interaction 
between MSCs and GBMs. 
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5.4. Viability Increase by MSC-CM is Mediated by the Soluble Factors in CM and 
the QKIs in GBMs 
I then investigated the cause of the increase in the viability by MSC-CM both from the MSC 
side and the GBM side. So, I sought answers to two questions: What do MSCs release into the 
medium that leads to an increase in the viability of GBMs? How do GBMs respond to the cues 
they receive from MSCs via CM? MSCs interact with other cells either via soluble factors they 
secrete or exosomes packed with signaling molecules which are released to the vicinity. I 
showed that the viability increase by the CM is mediated via the soluble factors that are 
secreted from MSCs. This was evident when the exosomes alone were not able to boost the 
viability of the GBMs but the CM devoid of exosomes showed an increase in the viability at a 
comparable level to that of native CM. 
To investigate the intracellular gene expression patterns in GBMs upon CM stimulation, a co-
regulated pathway analysis via a biclustering method was performed [Cheng and Church 
2000]. Upon statistical analyses and filtering relevant genes, QKIs emerged as candidates for 
the effect of MSC-CM on GBMs. Because, when global gene expression patterns were mapped 
comparing controls to CM-treated GBMs, activities of certain pathways shift further from the 
control in a time-dependent manner and QKI is at the central nodule of those pathways. 
Moreover, QKIs have been implicated in the tumor development as both pro- and anti-
tumorigenic. QKIs also have roles in cell cycle regulation [Biedermann et al., 2010]. 
Additionally, QKI-5 is implicated as a tumor suppressor and Fu et al. showed that QKI-5 has 
anti-tumorigenic effects via suppression of cyclin-D1 and in turn the MAPK pathway [Zhao et 
al., 2010; Fu et al., 2015]. Furthermore, Chen et al. discovered that, Quaking suppresses tumor 
growth via targeting specific miRNA via p53 pathway [Chen et al., 2012]. There are few studies 
showing pro-tumorigenic effects of QKIs [Wang et al., 2013; Bandopadhayay et al., 2016] and 
one publication is demonstrating QKI suppression by MiRNAs leading to tumor progression 
[Pillman et al., 2018]. In light of these previous research findings, I predicted that QKIs have 
pro-tumorigenic roles in brain tumors [Wang et al., 2013; Bandopadhayay et al., 2016], or 
some undiscovered pathway could be the mechanism by which the viability and sphere 
formation increases. 
In order to test if QKI is important for the increase in viability and proliferation, I used gene 
manipulation strategies. I showed that overexpression of QKIs, for isoforms QKI-5, QKI-6 and 
QKI-7, results in a marked increase in the viability of GBMs to the levels comparable to that 
mediated by CM. This increase in viability was, however, most prominent with elevation of 
QKI-6 expression. Additionally, in one line (Line 7) the knockdown of QKIs blunted the effect 
of MSC-CM in terms of viability increase. On the other hand, I carried out those overexpression 
experiments for QKIs only in classical GBM Line 4 and proneural GBM Line 7, as the increase 
in the viability was largest in those two lines, and they were more readily available than the 
other GBM lines, which is an important criterion for performing parallel experiments. 
Therefore, the overexpression of QKIs in mesenchymal subtype (the increase in viability of 
mesenchymal subtype was less compared to other subtypes) could lead to a different 
outcome or the other QKI isoforms than QKI-6 might prevail in terms of the increase in 
viability. 
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Furthermore, I showed that the increase in the viability was mediated by the soluble factors 
in CM, rather than the exosome-cargo. However, I did not explore which soluble factors take 
part in this phenomenon. Because I had two major directions to take: QKIs or exosome cargo 
which later proved to be related to invasion and more relevant to therapeutic intervention as 
they are not intracellular molecules unlike QKIs. Moreover, a body of research has been 
performed on QKIs. In one particular study, Wang et al. showed that QKI-5 and QKI-6 directly 
interacts with miRNA7 and sequesters it in the nucleus preventing it from being loaded onto 
and processed by the RISC complex, in glial cells. This interaction prevents the maturation of 
miRNA7, which targets EGFR [Wang et al., 2013]. Likewise, the knockdown of QKIs in Line 4 
lead to a decrease in the EGFR levels, which is in line with the findings by Wang et al. Therefore, 
Line 4 uses the same conserved mechanism from the glial cells, in terms of the QKI-
dependency. 
As mentioned above, a soluble factor mediates the increase in QKI levels and in turn viability 
and sphere formation. However, what leads to the overexpression of QKIs in GBM cells is still 
unknown. There might be some soluble peptides that are cleaved from the surface of MSCs 
and released into the cultivation medium, which in turn acts on a receptor on the GBM surface 
leading to a series of signal transductions converging on QKI pathways and causing an increase 
in the QKI levels. It could also be a peptide that is simply released to the medium which in turn 
acts as a ligand for a receptor. This phenomenon was demonstrated by some research groups 
where Ephrin ligand is cleaved from the cell surface and acts on Eph receptors at a distant site 
causing alterations in Eph receptor clustering or abundance on cell surface [Bartley et al. 1994; 
Hattori et al., 2000; Wykosky et al. 2008]. Similarly, exosome bound ligands are cleaved to 
become soluble peptides and act on distant receptors [McKelvey et al., 2015]. 
Alternatively, it could be a fatty acid or a fat compound that is released or deposited as a waste 
to the medium by MSCs causing a trigger in GBMs for cell division. I subjected CM to high 
temperature and applied onto GBMs and observed a decrease in the proliferation and viability 
of GBM cells compared to untreated control CM (Data not shown). Although fat compounds 
are more heat-resistant than peptides, such high temperature exposure (75 ˚C) is likely to 
cause distortions in structure causing a less functional or nonfunctional molecule, explaining 
the phenomenon. In fact, a system governing fatty acids released from MSCs exerting effects 
in tumors has been demonstrated by Roodhart et al. where they showed that platinum-
induced fatty acid release from MSCs confers cisplatin chemoresistance in murine tumors 
(Roodhart et al., 2011). 
5.5. Exosomes do not Cause Viability Increase but the Adherence and 
Morphological Changes 
I showed that, exosomes isolated by ultracentrifuge in a gradient did not yield any increase in 
viability (even when concentrated), however, CM that lacks exosomes (depleted by 
ultracentrifugation), boosted the viability of GBMs at a comparable level to native CM 
containing exosomes. I tried to recapitulate this by isolating exosomes with a commercially 
available exosome isolation reagent (Exoquick-TC kit). Contrary to the previous finding, 
however, exosomes caused a significant increase in the viability of GBMs only when they were 
applied onto GBMs in a concentrated way (5X-10X). This increase in the viability was not at a 
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comparable level to that of the native CM or EDCM and was completely lost when exosomes 
were less concentrated (3X or lower). One possible explanation for this observation could be 
that the Exoquick-TC kit is likely a lipophilic reagent clustering hydrophopic molecules such as 
cell membrane debris or hydrophobic proteins (along with exosomes) which are the agents 
that cause the viability increase in the CM. However, the concentration of those factors in 
exosome pellet is much lower than in CM. That is why, exosome pellet causes a slight increase 
in the viability when they are concentrated but fail to boost viability when below 3X 
concentration. Moreover, ultracentrifuge provides more reliable and pure exosomes. 
Therefore, I concluded the exosomes alone do not have the ability to increase the viability of 
GBMs. 
Additionally, the MSC-CM caused a morphological change in GBMs. The GBMs, which normally 
grow as floating spheroids, adhered to the plate and had protrusions in two opposing sides of 
the cells, reminiscent of migrating cells [Hakkinen et al., 2010]. GBM cells treated with the 
exosomes and CM had morphological changes but the EDCM completely lacked the adherence 
and the morphological changes. So, the morphology change and adherence were exclusively 
brought about by the exosomes. Moreover, the morphological changes due to CM and 
exosomes were observed the most in proneural subtype of GBMs, and the least in the classical 
subtype suggesting a subtype dependency of the observed phenotype. 
5.6. Exosome Cargo Contains and deposits EFNA3 into GBMs 
Exosomes are packed with proteins, mRNAs and miRNAs and released to the cell exterior 
[Mathivanan et al., 2009]. I hypothesized that some miRNAs or mRNAs mediate the 
morphology change and the adherence of GBM cells based on some publications which 
demonstrate the message transfer via exosomes. For instance; Tomasoni et al showed in 2013 
that MSCs can transfer growth factor receptor mRNAs via exosomes to proximal tubular 
epithelial cells causing an increase in their proliferation rate [Tomasoni et al., 2013]. 
Additionally, Ono et al in 2014 demonstrated that exosomes from MSCs carry a specific miRNA 
which renders metastatic breast cancer cells dormant [Ono et al., 2014]. Therefore, we 
performed an NGS readout with exosomes, and exosome-stimulated GBM cells. I analyzed the 
readouts by taking the cutoff value as 1,5X-fold change. From this analysis, a few miRNAs and 
some mRNAs emerged. EFNA3 has caught our attention, because there is already a body of 
research which describes the role of Eph-Ephrin signaling and their potential implications in 
cancer [Fertuga et al., 2014; Merloz-Suarez et al., 2008; Vail et al., 2014]. Seeing in numbers 
the direct transfer of EFNA3 mRNA from exosomes to GBMs where EFNA3 was abundant in 
exosomes and the abundance increased in the exosome treated GBMs but not in the vehicle 
treated ones was a supporting observation. That’s why I focused on EFNA3 in MSCs. 
5.7. EFNA3 Manipulation in MSCs 
EFNA3 knockdown in MSCs was performed with lentiviral vectors. After the selection of 
transduced MSCs, the amount of knockdown was tested with quantitative real-time PCR. 
Among three different knockdown vectors, one was selected as the most potent. However, 
even with the most potent knockdown, the highest amount of knockdown we could reach was 
52% reduction in gene expression. The knockdown of EFNA3 in MSCs reduced their growth 
rate, changed their morphology and decreased the adhesion of MSCs to the plate, which was 
72 
 
not observed in the MSCs transduced with non-targeting control vector. This observation was 
consistent with the finding that EFNA3 abundance is an important determinant of adherence 
and survival in MSCs [Alfaro and Zapata, 2018]. Furthermore, some cells in vivo and in vitro, 
require some contact inhibition in order not to malfunction or to prevent overgrowth. In the 
developmental processes, EFNA3 is known to be involved in the formation of tissue borders 
and axonal tracts by repulsive mechanisms [Palmer and Klein 2003]. It might be possible that 
EFNA3 also regulates the contact inhibition of MSCs and when we knock it down, the MSCs 
loses the contact inhibition too leading to malfunctioning [Hoffmann et al., 2009]. Overall, a 
large decrease of EFNA3 in MSCs might be harmful for their survival. This may explain the low 
amount of decrease in EFNA3 expression in MSCs upon knockdown as the surviving MSCs are 
those with relatively lower decrease in EFNA3 expression but not enough to cause detrimental 
outcomes. 
The exosomes alone do not lead to viability increase in GBMs when they are not concentrated, 
so I recapitulated this in terms of the effect of EFNA3 knockdown on viability of GBMs. The 
CM from MSCs with EFNA3 knockdown caused neither an increase nor a decrease in the 
viability of the GBMs compared to the non-targeting control (data not shown). This 
observation supports my hypothesis that EFNA3 in MSCs is not related to the increase in the 
viability, but it is related to the adherence and the morphological changes which potentially 
are related to a migratory behavior. 
5.8. EFNA3 Mediates the Migration of GBMs 
The effect of EFNA3 transfer from MSCs to GBMs within exosomes was observed as 
morphological changes (adherence and protrusions). Moreover, the percentage of the 
adherent GBM cells was reduced upon application of CM from MSCs with EFNA3 knockdown. 
Therefore, the effects of EFNA3 knockdown in MSCs on the GBM migration was tested. In 
order to do this, we first decided to plate a single or a few spheres in a well of a 96-well plate 
and measure the distance between the center of a sphere and the cells migrated furthest from 
the sphere center. However, plating more than one sphere posed a high ambiguity as 
migrating cells from different spheres mixed in with each other. Additionally, measuring the 
distance from the sphere center to the furthest-migrating cells also caused a problem with the 
normalization. The migrated distance was different for each sphere, proportional to the 
sphere size. Moreover, not all the spheres had the same migration pattern, such that some 
cells migrated as a thin line and migrated far, whereas some cells migrated not too far but 
spread in a larger area. So, the linear distance measurement didn’t fit to our purpose as it 
didn’t give us a reliable measurement of migration that can reflect the real difference between 
GBMs treated with CM from control and EFNA3-knockdown MSCs. That’s why I came up with 
the proportional measurement of the occupied surface area. In this system single spheres 
were plated in each well of a 96-well plate and the surface area of spheres was measured in 
two dimensions on day of plating (day zero) and the same spheres were followed for three 
days measuring the surface area occupied in two dimensions by the migrating cells. the total 
migrated area on each day was divided by the surface area of the respective spheres on day 
zero, in order to find the fold change in the occupied surface area. That way, I could normalize 
the migrated area to the initial size of the sphere which produced more precise 
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measurements.  This method was used repeatedly for most of the GBM cell types we had. 
However, some GBM lines do not form large enough spheres for reliable measurements of 
the initial size as well as the migrated area. This caused our experiments to be confined to the 
GBM lines forming large enough spheres. 
Furthermore, EFNA3 knockdown in MSCs did not alter the migration pattern of some GBM 
lines upon exposure to CM from those MSCs. These GBMs were almost always of 
mesenchymal subtype. Therefore, the migratory behavior observed in the mesenchymal 
subtypes of GBMs may not be related to EFNA3 in MSCs. Additionally, classical subtypes did 
not adhere or migrate upon MSC-CM exposure (only increase in viability). As a result, our 
experiments regarding the effects of EFNA3 in MSCs on the migration of GBMs were confined 
to proneural subtype of GBMs only. 
Those observations lead to a question about the mechanism of action of EFNA3 in the 
migration of GBMs and about the subtype dependency of CM-mediated migration of GBMs. 
We have found evidence supporting the view of direct transfer of EFNA3 mRNA from MSCs to 
GBMs via exosomes. EFNA3 locus harbors a few transcription start sites which are activated 
by hypoxia, leading to nonfunctional proteins which are not integrated into plasma 
membrane. Interestingly, those long noncoding RNAs act as competing partners for MiRNAs 
which target EFNA3, increasing EFNA3 protein abundance in cells causing metastatic 
dissemination in breast cancer [Gomez-Maldonado et al., 2014]. So, the EFNA3 mRNA 
delivered via exosomes might be such noncoding EFNA3 mRNA sequences that cause elevate 
the translation of endogenous EFNA3 proteins causing such mobilization and metastatic 
behavior.  Those nonfunctional mRNAs may not have been distinguished in RNASeq due to 
arbitrary sequencing of all RNA content in a given sample leading to annotation of even 
shorter sequences as the intact RNA. Moreover, delivery of coding EFNA3 mRNA via into the 
GBM cells via exosomes might act in the same way as long noncoding EFNA3 mRNAs leading 
to the same outcome. 
Alternatively, in each sphere, there might be a balance between EFNA3- and EphA-expressing 
cells in terms of abundance. Upon translation of EFNA3 in cells receiving exosomes and 
integration into the plasma membrane, this balance is distorted causing repulsive interactions 
to increase, leading cells migrating away from each other. It might even be that some cells 
have expression of both the ligand and the receptor in a certain ratio which is also distorted 
upon exosome reception. Therefore, the endogenous EFNA3 expression levels in GBMs might 
be important for the determination of the migratory behavior caused by EFNA3 that is 
deposited into them via exosomes from MSCs. Proneural GBMs express EFNA3 more than 
mesenchymal subtype [Lottaz et al., 2010]. Addition of more EFNA3 on the cell membrane in 
proneural subtypes may shift this balance towards EFNA3 causing repulsion and migration. 
However, mesenchymal subtype GBMs do not possess significant amounts of EFNA3 on 
plasma membrane, so addition of EFNA3 might not be enough to drive migration, as I showed 
that mesenchymal GBM cell migration is unrelated to EFNA3, supporting the hypothesis. 
Furthermore, I tested the effects of EFNA3 on GBMs in an independent system by expressing 
EFNA3 in HEK-293 cells and performing the migration assays for GBMs with CM from those 
HEK-293 cells overexpressing EFNA3 in the same way as for the MSC-CM. GBMs that were 
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stimulated with CM from EFNA3-overexpressing HEK293 cells migrated to significantly larger 
areas compared to those stimulated with CM from HEK293 cells carrying the empty vector. 
However, this increase was lower than the levels obtained with MSC-CM. This might be due 
to lower amounts of packaging of EFNA3 mRNA into exosomes. It might even be that the 
exosomes are loaded with EFNA3 protein, but not the mRNA. Yet, this still proves the fact that 
EFNA3 is involved in the migratory stimulation of GBMs. 
Epithelial to mesenchymal transition (EMT) is one of the major mechanisms of cancer cell 
metastasis. Although CNS lacks the critical component required for such migration, which is 
the basement membrane (epithelial structure), the key invasion mechanisms overlap between 
CNS and peripheral tumors [Kahlert et al., 2013]. However, Vimentin (an intermediate 
filament required and used as marker for EMT) staining did not show a significant difference 
between GBMs that are cultivated in the presence of CM and control medium. Supporting this 
finding, Kahlert et al. demonstrated in 2012 that, migrating GBMs display properties similar to 
GBM mesenchymal subtype through activation of Wnt/β-catenin signaling, making it 
untraceable by vimentin (Kahlert et al. 2012). This might mean that GBMs exposed to MSC-
CM might gain mesenchymal phenotype (from proneural and classical subtypes into 
mesenchymal phenotypes) which brings also the migratory phenotype. Additionally, in the 
RNASeq data, CD44 (a mesenchymal marker) expression was increased in the GBMs which 
received exosomes compared to controls. Moreover, CD133 and Nestin staining in GBM cells 
which were exposed to CM were increased compared to controls, suggesting more stem-like 
characteristics of mesenchymal GBMs consistent with the other studies [Lottaz et al., 2010]. 
Overall, these observations support that serum-free MSC-CM, and the MSCs in the satellite 
GBMs, render GBMs more mesenchymal (and stem-like) and cause their migration and 
invasion. 
In light of those findings, it can be concluded that EFNA3 is the main mediator of the migration 
in proneural GBMs and also causes a mesenchymal shift. Using this information, EFNA3 
blockers can be developed and tested for efficacy in vitro and in vivo in terms of the prevention 
of the migration. Those EFNA3 blockers then can be used to perform a helping treatment in 
GBMs. MSCs home better the satellite tumors, which are the sources of tumor recurrence and 
deeper infiltration. Therefore, the EFNA3 blockade can help prevent the more diffuse 
spreading of the GBMs. When satellites develop into larger tumors, they can be easily resected 
with no risk of leaving infiltrated cells behind which causes the recurrence. This, altogether, 
might lead to prolonged survival. 
However, a major problem could be the localization and abundance of EFNA3 in the body. 
Eph-Ephrin signaling is important in developmental processes such as in the formation of 
axonal tracts. In the adulthood they continue to function as boundaries between different 
tissues or different parts of a specific organ. They are especially abundant in brain. Ephrin-A3 
plays a role in the long-term potentiation formation in the brain as well as neuron-glia 
interactions (Filosa et al, 2009). Furthermore, Ephrin ligand family members have significant 
sequential and structural similarities which might cause non-specific targeting by the blocker. 
Therefore, administration of EFNA3 blockers might interfere with nonspecific targets within 
the body. 
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5.9. MSCs did not Alter the Median Survival 
In addition to showing that the MSCs home satellite tumors better than the main tumor mass, 
we tested the effect of MSCs on the overall survival rate. The MSCs were again inoculated 
along with the GBMs. The GBM we inoculated (classical subtype) responded to CM by a 
significant increase of viability in vitro. Therefore, it was expected to become more aggressive 
in the presence of MSCs leading to a shorter median survival. However, the difference 
between median survival of the mice inoculated with GBM cells along with MSCs were not 
significantly different from those with GBM cells alone. This might be due to more factors 
coming into play in vivo from which GBMs receive signals that cannot be controlled. 
Additionally, it is not certain if MSCs were completely isolated from the blood-borne cues, 
contrary to the in vitro serum-free conditions, which make them more antitumorigenic (Figure 
1). Additionally, it was shown by others [Stoff-Khalili et al., 2007; Mohr et al., 2010] and us 
that MSCs home satellites better than main tumor mass. As being an early study, we only 
tested for the survival, rather than infiltration and recurrence, where MSCs have more 
relevance to the clinical situation. Therefore, removal of the main tumor mass and tracking of 
a relapse in the presence of MSCs would be a better approach in terms of the effects of MSCs 
in GBM pathogenesis. 
Moreover, MSCs which are infused systematically into the blood stream in vivo have been 
shown to be gradually decreasing after 24 hours [Saat et al., 2016; Xie et al., 2017] becoming 
nondetectable after 14 days [Kidd et al., 2009]. In our experimental setting, we inoculated 
MSCs directly into the brain tissue, close to the tumor xenograft, which may have provided a 
longer survival of them until they reach the tumor. Yet, this does not ensure sustained effects 
of MSCs on the tumor. Therefore, a repeated systematic injection is required to achieve a 
stable quantity of MSCs within the tumor which also would be a less invasive approach. 
5.10. Information Transfer Between MSCs and GBMs 
In the NGS of exosomes and the GBMs that were stimulated with the exosomes, we have 
demonstrated the existence of information transfer from MSCs to GBMs. In addition, we 
proved the transfer of the information exchange in an experimental setting in vitro. In this 
setting, we used a system where Cre-recombinase fused with ERT2 is expressed in MSCs and 
a flipped-reporter-GFP is expressed in GBMs. This system provides a tamoxifen-inducible 
labelling of GBMs allowing detection of interactions at a certain time point. And upon 
tamoxifen induction, the GBMs receiving Cre-ERT2 from MSCs are permanently labelled with 
GFP allowing tracking of individual cells receiving signals from MSCs. With this experimental 
system, the information transfer took place in some 5-8% of the GBMs as the MSC population 
was not completely selected for the existence of the positive selection marker for puromycin 
resistance. On the other hand, the message that is transferred from MSCs to GBMs requires 
being packaged into exosomes. We demonstrated the packaging of EFNA3 and Cre-
recombinase packaging was established by others [Ridder et al., 2012]. However, we are not 
sure about whether mRNA or protein of Cre-ERT2 locus is packaged into exosomes as well as 
to what extent this packaging takes place in MSCs, contrary to the findings of Ridder et al, who 
demonstrated the packaging of Cre-ERT2 mRNA into exosomes in cells from hematopoietic 
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lineage. That’s why further optimizations are required to achieve a higher rate of 
recombination events. 
Furthermore, we would like to combine this system with the TK system in a way that one GBM 
cell will have both systems (TK and Flip-GFP). This way, with GCV, we will annihilate most of 
the GBM cells (with the TK suicide gene) causing formation of satellite tumors and the MSCs 
carrying Cre-recombinase insert will home the remaining satellites. Via the information 
transfer, the GBMs which receive exosomes from MSCs will be marked with GFP permanently. 
This system, therefore, will allow us to follow the behavior of each GBM which receive 
exosomes from MSCs in terms of proliferation and migration. 
5.11. MSCs Render GBMs Chemoresistant 
There is a body of research about MSCs being involved in chemoresistance in tumors 
(Roodhart et al, 2011; Ji et al, 2016; Maj et al, 2017). So, I also tested the effects of MSCs on 
GBMs in terms of chemoresistance. Some GBM lines which are killed by TMZ under normal 
conditions become more resistant and some of them are completely irresponsive to TMZ 
when they are cultivated in MSC-CM. QKI proved to be important in this phenomenon. As both 
CM and the QKI overexpression (via increase in EGFR levels) in common mediate proliferation, 
the chemoresistance effect could be related to a decrease in TMZ/cell ratio as the cells in CM 
will proliferate faster than those in control medium, allowing GBM cells to escape the cell cycle 
arrest due to damage to DNA introduced by TMZ. Additionally, via immunocytochemical 
methods, I found out that MSC-CM increases the stem cell markers, such as CD133 and Nestin 
as well as the proliferation marker Ki67, in GBMs and decrease the differentiation markers. 
Moreover, a mesenchymal subtype shift is observed in GBMs upon exposure to MSC-CM 
(mentioned above). Mesenchymal GBM subtype expresses relatively more stem-cell markers 
and they are more resistant to genotoxic insults leading to a more aggressive phenotype. 
These show that the GBMs become more mesenchymal, stem-like and chemoresistant and 
eventually more aggressive upon contact with MSCs in serum-free conditions. 
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6. CONCLUSION 
In this study, I demonstrated that MSCs home GBMs, especially at the invasive tumor front, 
i.e. tumor satellites where they are away from bloodstream. In serum-free in vitro conditions 
mimicking the satellite tumor microenvironment, they act as pro-tumorigenic by elevating 
proliferation and viability of GBMs via signaling through soluble factors leading to an increase 
in intracellular QKI levels, thereby de-repressing and increasing EGFR levels. Moreover, via 
EFNA3 mRNA packaged into exosomes they release, they enhance the migration of GBMs. 
Furthermore, they render GBMs chemoresistant against the conventional therapeutic agent, 
TMZ. MSCs cause a mesenchymal shift in the proneural and classical subtype of GBMs leading 
to more stem-like and invasive phenotype, which, likely, accounts for the significant increase 
in migration and chemoresistance. 
MSCs are more relevant to the relapse of GBMs in the clinical scenario where main tumor is 
removed leaving deep infiltrative cells and satellites. Thereafter, MSCs cause regrowth and 
further infiltration of GBMs to the surrounding tissue. In order to study this pathological 
situation, we developed a tumor satellite model where GBMs expressing TK suicide gene are 
treated with systematical GCV injection, causing elimination of a majority of GBM cells, leaving 
small quantities which form satellite tumors. Additionally, we developed a system to test the 
mRNA transfer from MSCs to GBMs utilizing a Cre-ERT2 fusion gene expression in MSCs and a 
flipped-GFP expression in GBMs. This system allows for the demonstration of direct message 
transfer from MSCs to GBMs, for the temporal control over the recombination events as well 
as for permanent labelling of GBM cells which receive exosomes from MSCs making them 
trackable throughout the development of the tumor. However, this system requires further 
optimization in terms of the efficiency and frequency of the transfer and recombination 
events. 
Future studies will utilize the Cre-ERT2 and Flipped-GFP system in combination with the 
satellite tumor model, in order to investigate the interaction between MSCs and GBMs at 
satellite tumors, permanently labelling GBM cells receiving exosomes from MSCs so that they 
could be tracked during their development in terms of migration as MSC exosomes cause 
migration of GBMs. Furthermore, EFNA3 blockade will be tested for preventing MSC-mediated 
migration of GBM cells. Overall, these findings shed light on the MSC-GBM interactions 
further, describe a, to our knowledge, previously unknown EFNA3 transfer, and the developed 
methods enable us to perform further experimentations more precisely in order to investigate 
the effects of MSCs on GBMs further. 
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Supplementary Figure 1: CM rescues GBMs from TMZ effects. Additional lines were 
subjected to TMZ in DMEM or CM from MSCs (serum-free). The calculation of total cell 
numbers was described above (Figure 8). GBMs treated with TMZ cultivated in CM had 
larger numbers of cells compared to those cultivated in control (DMEM).  
